0001829247 2024-01-01 2024-09-30 0001829247 dei:BusinessContactMember 2024-01-01 2024-09-30 0001829247 2024-09-30 0001829247 2023-12-31 0001829247 2022-12-31 0001829247 us-gaap:NonrelatedPartyMember 2023-12-31 0001829247 us-gaap:NonrelatedPartyMember 2022-12-31 0001829247 us-gaap:RelatedPartyMember 2023-12-31 0001829247 us-gaap:RelatedPartyMember 2022-12-31 0001829247 BFRG:SeriesAConvertiblePreferredStockMember 2024-09-30 0001829247 BFRG:SeriesAConvertiblePreferredStockMember 2023-12-31 0001829247 BFRG:SeriesAConvertiblePreferredStockMember 2022-12-31 0001829247 2024-07-01 2024-09-30 0001829247 2023-07-01 2023-09-30 0001829247 2023-01-01 2023-09-30 0001829247 2023-01-01 2023-12-31 0001829247 2022-01-01 2022-12-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-12-31 0001829247 us-gaap:CommonStockMember 2022-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001829247 us-gaap:RetainedEarningsMember 2022-12-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-03-31 0001829247 us-gaap:CommonStockMember 2023-03-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001829247 us-gaap:RetainedEarningsMember 2023-03-31 0001829247 2023-03-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-06-30 0001829247 us-gaap:CommonStockMember 2023-06-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001829247 us-gaap:RetainedEarningsMember 2023-06-30 0001829247 2023-06-30 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-12-31 0001829247 us-gaap:CommonStockMember 2023-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001829247 us-gaap:RetainedEarningsMember 2023-12-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-03-31 0001829247 us-gaap:CommonStockMember 2024-03-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001829247 us-gaap:RetainedEarningsMember 2024-03-31 0001829247 2024-03-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-06-30 0001829247 us-gaap:CommonStockMember 2024-06-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001829247 us-gaap:RetainedEarningsMember 2024-06-30 0001829247 2024-06-30 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001829247 us-gaap:CommonStockMember 2021-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001829247 us-gaap:RetainedEarningsMember 2021-12-31 0001829247 2021-12-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-03-31 0001829247 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001829247 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001829247 2023-01-01 2023-03-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-04-01 2023-06-30 0001829247 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001829247 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001829247 2023-04-01 2023-06-30 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-07-01 2023-09-30 0001829247 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001829247 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-01-01 2024-03-31 0001829247 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001829247 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001829247 2024-01-01 2024-03-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-04-01 2024-06-30 0001829247 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001829247 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001829247 2024-04-01 2024-06-30 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-07-01 2024-09-30 0001829247 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001829247 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001829247 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001829247 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-01-01 2023-12-31 0001829247 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001829247 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2023-09-30 0001829247 us-gaap:CommonStockMember 2023-09-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001829247 us-gaap:RetainedEarningsMember 2023-09-30 0001829247 2023-09-30 0001829247 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2024-09-30 0001829247 us-gaap:CommonStockMember 2024-09-30 0001829247 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001829247 us-gaap:RetainedEarningsMember 2024-09-30 0001829247 BFRG:UnderwrittenPublicOfferingMember 2024-02-01 2024-02-29 0001829247 us-gaap:SubsequentEventMember 2024-10-01 2024-10-31 0001829247 us-gaap:SubsequentEventMember BFRG:UnderwrittenPublicOfferingMember 2024-02-29 2024-02-29 0001829247 us-gaap:SubsequentEventMember BFRG:UnderwrittenPublicOfferingMember 2024-02-29 0001829247 us-gaap:SubsequentEventMember us-gaap:OverAllotmentOptionMember 2024-02-21 2024-02-21 0001829247 us-gaap:IPOMember 2023-02-01 2023-02-28 0001829247 us-gaap:IPOMember 2023-02-13 2023-02-13 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-31 0001829247 BFRG:ConvertibleLoanAgreementMember 2021-08-01 2021-08-31 0001829247 us-gaap:NonrelatedPartyMember BFRG:ConvertibleLoanAgreementMember 2021-08-31 0001829247 us-gaap:NonrelatedPartyMember BFRG:LoanAgreementMember 2021-12-01 2021-12-31 0001829247 us-gaap:NonrelatedPartyMember BFRG:LoanAgreementMember 2021-12-31 0001829247 BFRG:ConvertibleBridgeNotesMember 2022-01-01 2022-12-31 0001829247 BFRG:ConvertibleBridgeNotesMember 2023-02-01 2023-02-28 0001829247 BFRG:ConvertibleLoanAgreementMember BFRG:MarylandTechnologyDevelopmentCorporationMember 2020-03-27 0001829247 BFRG:ConvertibleLoanAgreementMember BFRG:MarylandTechnologyDevelopmentCorporationMember 2020-03-27 2020-03-27 0001829247 BFRG:ConvertibleLoanAgreementMember BFRG:MarylandTechnologyDevelopmentCorporationMember 2022-01-01 2022-12-31 0001829247 us-gaap:NonrelatedPartyMember BFRG:ConvertibleLoanAgreementMember 2021-08-01 2021-08-31 0001829247 us-gaap:NonrelatedPartyMember BFRG:ConvertibleLoanAgreementMember 2021-01-01 2021-12-31 0001829247 us-gaap:NonrelatedPartyMember BFRG:ConvertibleLoanAgreementMember 2022-01-01 2022-12-31 0001829247 us-gaap:NonrelatedPartyMember BFRG:ConvertibleLoanAgreementMember 2022-12-31 0001829247 us-gaap:NonrelatedPartyMember BFRG:ConvertibleLoanAgreementMember 2022-05-31 0001829247 us-gaap:NonrelatedPartyMember BFRG:LoanAgreementMember 2021-12-20 2021-12-20 0001829247 us-gaap:NonrelatedPartyMember BFRG:LoanAgreementMember 2021-12-20 0001829247 us-gaap:NonrelatedPartyMember BFRG:LoanAgreementMember 2022-04-01 2022-04-30 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember 2022-04-28 2022-04-28 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember us-gaap:RelatedPartyMember 2022-04-28 2022-04-28 0001829247 BFRG:ConvertibleBridgeNotesAndWarrantsMember us-gaap:NonrelatedPartyMember 2022-09-01 2022-09-30 0001829247 BFRG:ConvertibleBridgeNotesMember 2022-09-01 2022-09-30 0001829247 us-gaap:WarrantMember 2022-09-01 2022-09-30 0001829247 BFRG:ConvertibleBridgeNotesMember 2022-12-31 0001829247 BFRG:ConvertibleBridgeNotesMember 2023-02-28 2023-02-28 0001829247 us-gaap:RelatedPartyMember BFRG:SimpleAgreementForFutureEquityMember 2021-07-31 0001829247 BFRG:SimpleAgreementForFutureEquityMember 2023-02-01 2023-02-28 0001829247 BFRG:ConvertibleLoanAgreementMember 2023-02-01 2023-02-28 0001829247 us-gaap:RelatedPartyMember BFRG:SimpleAgreementForFutureEquityMember 2021-07-08 0001829247 BFRG:SimpleAgreementForFutureEquityMember 2023-02-28 2023-02-28 0001829247 BFRG:SimpleAgreementForFutureEquityMember 2022-12-31 0001829247 us-gaap:RelatedPartyMember BFRG:ConvertibleLoanAgreementMember 2021-08-19 0001829247 us-gaap:RelatedPartyMember BFRG:ConvertibleLoanAgreementMember 2021-08-18 2021-08-19 0001829247 us-gaap:RelatedPartyMember BFRG:ConvertibleLoanAgreementMember 2023-02-28 2023-02-28 0001829247 us-gaap:RelatedPartyMember BFRG:ConvertibleLoanAgreementMember 2023-02-28 0001829247 us-gaap:RelatedPartyMember BFRG:NewLoanAgreementMember 2022-05-31 0001829247 2023-01-31 0001829247 2023-02-01 2023-02-28 0001829247 2024-02-01 2024-02-29 0001829247 2023-12-01 2023-12-31 0001829247 srt:MinimumMember BFRG:InvestorsMember 2024-09-30 0001829247 us-gaap:IPOMember 2023-02-28 0001829247 BFRG:TradeableWarrantsMember 2023-02-01 2023-02-28 0001829247 BFRG:TradeableWarrantsMember 2023-02-28 0001829247 BFRG:NonTradeableWarrantsMember 2023-02-01 2023-02-28 0001829247 BFRG:NonTradeableWarrantsMember 2023-02-28 0001829247 us-gaap:CommonStockMember us-gaap:IPOMember 2023-02-01 2023-02-28 0001829247 us-gaap:CommonStockMember 2023-02-01 2023-02-28 0001829247 BFRG:PrefundedWarrantsMember BFRG:UnderwrittenPublicOfferingMember 2024-02-01 2024-02-29 0001829247 us-gaap:WarrantMember BFRG:UnderwrittenPublicOfferingMember 2024-02-01 2024-02-29 0001829247 us-gaap:OverAllotmentOptionMember 2024-02-29 0001829247 BFRG:UnderwrittenPublicOfferingMember 2024-02-29 0001829247 BFRG:UnderwrittenPublicOfferingMember 2023-02-24 0001829247 us-gaap:PreferredStockMember 2024-09-30 0001829247 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001829247 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001829247 us-gaap:PreferredStockMember 2023-09-30 0001829247 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001829247 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001829247 BFRG:TwoThousandTwentyTwoEquityIncentivePlanMember 2022-11-01 2022-11-30 0001829247 us-gaap:WarrantMember 2023-02-28 0001829247 us-gaap:WarrantMember 2024-09-30 0001829247 us-gaap:WarrantMember 2024-02-29 0001829247 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001829247 us-gaap:WarrantMember BFRG:UnderwritersMember 2023-02-28 0001829247 us-gaap:WarrantMember BFRG:UnderwritersMember 2024-02-29 0001829247 us-gaap:WarrantMember BFRG:UnderwritersMember 2024-01-01 2024-09-30 0001829247 BFRG:TradableWarrantMember 2023-02-28 0001829247 BFRG:TradableWarrantMember 2024-09-30 0001829247 BFRG:NonTradableWarrantMember 2023-02-28 0001829247 BFRG:NonTradableWarrantMember 2024-09-30 0001829247 BFRG:TradableWarrantMember us-gaap:OverAllotmentOptionMember 2023-02-28 0001829247 BFRG:NonTradableWarrantMember us-gaap:OverAllotmentOptionMember 2023-02-28 0001829247 us-gaap:WarrantMember us-gaap:OverAllotmentOptionMember 2024-09-30 0001829247 BFRG:TradableWarrantMember us-gaap:OverAllotmentOptionMember 2024-09-30 0001829247 BFRG:PrefundedWarrantMember 2024-01-01 2024-09-30 0001829247 BFRG:PrefundedWarrantMember 2024-09-30 0001829247 us-gaap:WarrantMember BFRG:UnderwritersMember 2024-09-30 0001829247 us-gaap:WarrantMember 2024-07-01 2024-09-30 0001829247 us-gaap:WarrantMember 2023-07-01 2023-09-30 0001829247 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001829247 BFRG:UnvestedWarrantsMember 2024-09-30 0001829247 us-gaap:InvestorMember us-gaap:CommonStockMember BFRG:ExchangeAgreementMember 2022-10-04 2022-10-05 0001829247 us-gaap:InvestorMember BFRG:SeriesAConvertiblePreferredStockMember BFRG:ExchangeAgreementMember 2022-10-04 2022-10-05 0001829247 us-gaap:InvestorMember BFRG:SeriesAConvertiblePreferredStockMember BFRG:ExchangeAgreementMember 2022-10-05 0001829247 srt:MinimumMember BFRG:InvestorsMember BFRG:ExchangeAgreementMember 2022-10-05 0001829247 us-gaap:InvestorMember us-gaap:SeriesAPreferredStockMember BFRG:ExchangeAgreementMember 2022-10-05 0001829247 us-gaap:SeriesAPreferredStockMember BFRG:ExchangeAgreementMember 2022-01-01 2022-12-31 0001829247 BFRG:PriorAgreementsAndNewAgreementsMember 2022-01-01 2022-12-31 0001829247 us-gaap:CommonStockMember BFRG:LicenseAgreementMember 2022-01-01 2022-12-31 0001829247 us-gaap:WarrantMember 2023-04-01 2023-06-30 0001829247 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001829247 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001829247 BFRG:TwentyTwentyTwoEquityIncentivePlanMember 2022-11-01 2022-11-30 0001829247 srt:MaximumMember BFRG:TwentyTwentyTwoEquityIncentivePlanMember 2022-11-30 0001829247 BFRG:TwentyTwentyTwoEquityIncentivePlanMember 2023-12-31 0001829247 us-gaap:StockOptionMember 2023-01-01 2023-12-31 0001829247 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001829247 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001829247 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001829247 us-gaap:WarrantMember 2022-12-31 0001829247 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001829247 BFRG:AdvisorsMember us-gaap:WarrantMember 2021-01-01 2021-12-31 0001829247 BFRG:AdvisorsMember us-gaap:WarrantMember 2021-12-31 0001829247 us-gaap:WarrantMember 2021-12-31 0001829247 us-gaap:WarrantMember 2022-06-30 2022-06-30 0001829247 us-gaap:WarrantMember BFRG:ConvertibleBridgeDebtAgreementsMember 2021-12-31 0001829247 us-gaap:WarrantMember 2022-06-30 0001829247 us-gaap:WarrantMember 2022-05-31 0001829247 us-gaap:WarrantMember BFRG:NewAgreementsMember 2022-05-31 0001829247 BFRG:WarrantOneMember 2022-05-31 0001829247 BFRG:WarrantOneMember BFRG:NewAgreementsMember 2022-05-31 0001829247 BFRG:DebtHoldersMember us-gaap:WarrantMember us-gaap:IPOMember 2023-02-28 0001829247 BFRG:UnderwritersMember us-gaap:WarrantMember us-gaap:IPOMember 2023-02-28 0001829247 BFRG:TradeableWarrantsMember us-gaap:IPOMember 2023-02-28 0001829247 BFRG:NonTradeableWarrantsMember us-gaap:IPOMember 2023-02-28 0001829247 BFRG:TradeableWarrantsMember us-gaap:OverAllotmentOptionMember 2023-02-28 0001829247 BFRG:NonTradeableWarrantsMember us-gaap:OverAllotmentOptionMember 2023-02-28 0001829247 BFRG:UnvestedWarrantsMember 2023-12-31 0001829247 BFRG:UnvestedWarrantsMember 2023-01-01 2023-12-31 0001829247 2021-01-01 2021-12-31 0001829247 srt:MinimumMember 2024-01-01 2024-09-30 0001829247 srt:MaximumMember 2024-01-01 2024-09-30 0001829247 srt:MinimumMember 2023-01-01 2023-09-30 0001829247 srt:MaximumMember 2023-01-01 2023-09-30 0001829247 srt:MinimumMember 2023-01-01 2023-12-31 0001829247 srt:MaximumMember 2023-01-01 2023-12-31 0001829247 BFRG:ExercisePriceMember 2024-09-30 0001829247 BFRG:ExercisePriceMember 2024-01-01 2024-09-30 0001829247 srt:MinimumMember BFRG:ExercisePriceOneMember 2024-09-30 0001829247 srt:MaximumMember BFRG:ExercisePriceOneMember 2024-09-30 0001829247 srt:MinimumMember BFRG:ExercisePriceOneMember 2024-01-01 2024-09-30 0001829247 srt:MaximumMember BFRG:ExercisePriceOneMember 2024-01-01 2024-09-30 0001829247 BFRG:ExercisePriceOneMember 2024-09-30 0001829247 srt:MinimumMember BFRG:ExercisePriceTwoMember 2024-09-30 0001829247 srt:MaximumMember BFRG:ExercisePriceTwoMember 2024-09-30 0001829247 srt:MinimumMember BFRG:ExercisePriceTwoMember 2024-01-01 2024-09-30 0001829247 srt:MaximumMember BFRG:ExercisePriceTwoMember 2024-01-01 2024-09-30 0001829247 BFRG:ExercisePriceTwoMember 2024-09-30 0001829247 srt:MinimumMember BFRG:ExercisePriceThreeMember 2024-09-30 0001829247 srt:MaximumMember BFRG:ExercisePriceThreeMember 2024-09-30 0001829247 srt:MinimumMember BFRG:ExercisePriceThreeMember 2024-01-01 2024-09-30 0001829247 srt:MaximumMember BFRG:ExercisePriceThreeMember 2024-01-01 2024-09-30 0001829247 BFRG:ExercisePriceThreeMember 2024-09-30 0001829247 BFRG:ExercisePriceFourMember 2024-09-30 0001829247 srt:MinimumMember BFRG:ExercisePriceFourMember 2024-01-01 2024-09-30 0001829247 srt:MaximumMember BFRG:ExercisePriceFourMember 2024-01-01 2024-09-30 0001829247 BFRG:ExercisePriceMember 2023-12-31 0001829247 BFRG:ExercisePriceMember 2023-01-01 2023-12-31 0001829247 srt:MinimumMember BFRG:ExercisePriceOneMember 2023-12-31 0001829247 srt:MaximumMember BFRG:ExercisePriceOneMember 2023-12-31 0001829247 srt:MinimumMember BFRG:ExercisePriceOneMember 2023-01-01 2023-12-31 0001829247 srt:MaximumMember BFRG:ExercisePriceOneMember 2023-01-01 2023-12-31 0001829247 BFRG:ExercisePriceOneMember 2023-12-31 0001829247 srt:MinimumMember BFRG:ExercisePriceTwoMember 2023-12-31 0001829247 srt:MaximumMember BFRG:ExercisePriceTwoMember 2023-12-31 0001829247 srt:MinimumMember BFRG:ExercisePriceTwoMember 2023-01-01 2023-12-31 0001829247 srt:MaximumMember BFRG:ExercisePriceTwoMember 2023-01-01 2023-12-31 0001829247 BFRG:ExercisePriceTwoMember 2023-12-31 0001829247 srt:MinimumMember BFRG:ExercisePriceThreeMember 2023-12-31 0001829247 srt:MaximumMember BFRG:ExercisePriceThreeMember 2023-12-31 0001829247 srt:MinimumMember BFRG:ExercisePriceThreeMember 2023-01-01 2023-12-31 0001829247 srt:MaximumMember BFRG:ExercisePriceThreeMember 2023-01-01 2023-12-31 0001829247 BFRG:ExercisePriceThreeMember 2023-12-31 0001829247 BFRG:ExercisePriceFourMember 2023-12-31 0001829247 srt:MinimumMember BFRG:ExercisePriceFourMember 2023-01-01 2023-12-31 0001829247 srt:MaximumMember BFRG:ExercisePriceFourMember 2023-01-01 2023-12-31 0001829247 us-gaap:WarrantMember 2023-12-31 0001829247 BFRG:JHUAPLTechnologyLicenseAgreementMember 2021-10-31 0001829247 BFRG:JHUAPLTechnologyLicenseAgreementMember 2021-10-01 2021-10-31 0001829247 BFRG:JHUAPLTechnologyLicenseAgreementMember 2022-01-01 2022-12-31 0001829247 BFRG:JHUAPLTechnologyLicenseAgreementMember 2023-01-01 2023-12-31 0001829247 srt:ScenarioForecastMember BFRG:JHUAPLTechnologyLicenseAgreementMember 2024-01-01 2024-12-31 0001829247 BFRG:NewLicenseAgreementMember 2022-07-01 2022-07-31 0001829247 BFRG:OtherPartiesMember BFRG:NewLicenseAgreementMember 2022-07-31 0001829247 BFRG:InternallyDevelopmentDrugProjectsMember BFRG:NewLicenseAgreementMember 2022-07-31 0001829247 srt:MaximumMember BFRG:NewLicenseAgreementMember 2022-07-31 0001829247 srt:MinimumMember BFRG:NewLicenseAgreementMember 2022-07-31 0001829247 BFRG:TwoThousandTwentyTwoYearMember BFRG:NewLicenseAgreementMember 2022-07-01 2022-07-31 0001829247 BFRG:TwoThousandTwentyThreeYearMember BFRG:NewLicenseAgreementMember 2022-07-01 2022-07-31 0001829247 BFRG:TwoThousandTwentyFourYearAndBeyondMember BFRG:NewLicenseAgreementMember 2022-07-01 2022-07-31 0001829247 BFRG:FromTwoThousandAndTwentyThreeThroughTwoThousandAndTwentySevenMember BFRG:NewLicenseAgreementMember 2023-05-31 0001829247 BFRG:JulyTwoThousandTwentyThreeMember BFRG:NewLicenseAgreementMember 2023-05-01 2023-05-31 0001829247 BFRG:TwoThousandTwentyFiveYearMember BFRG:NewLicenseAgreementMember 2023-05-01 2023-05-31 0001829247 BFRG:TwoThousandTwentySixYearMember BFRG:NewLicenseAgreementMember 2023-05-01 2023-05-31 0001829247 BFRG:TwoThousandTwentySevenYearMember BFRG:NewLicenseAgreementMember 2023-05-01 2023-05-31 0001829247 BFRG:TwoThousandTwentyThreeYearMember BFRG:NewLicenseAgreementMember 2023-05-01 2023-05-31 0001829247 BFRG:TwoThousandTwentyFourYearMember BFRG:NewLicenseAgreementMember 2024-09-30 0001829247 BFRG:GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember 2022-01-31 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-28 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-01 2022-02-28 0001829247 us-gaap:IPOMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-01 2022-02-28 0001829247 BFRG:TwoThousandTwentyTwoYearMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-01 2022-02-28 0001829247 BFRG:TwoThousandTwentyThreeYearMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-01 2022-02-28 0001829247 BFRG:TwoThousandTwentyFourYearMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-01 2022-02-28 0001829247 BFRG:TwoThousandTwentyFiveYearMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-01 2022-02-28 0001829247 BFRG:TwoThousandTwentySixYearMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-01 2022-02-28 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2024-09-30 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2023-12-31 0001829247 BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-31 0001829247 BFRG:TwoThousandTwentySixYearMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-01 2022-10-31 0001829247 BFRG:TwoThousandTwentySevenYearMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-01 2022-10-31 0001829247 BFRG:TwoThousandTwentyEightYearMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-01 2022-10-31 0001829247 BFRG:TwoThousandTwentyNineYearMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-01 2022-10-31 0001829247 BFRG:TwoThousandThirtyYearMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-01 2022-10-31 0001829247 BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-01 2022-10-31 0001829247 BFRG:YearTwentyTwentyTwoMember BFRG:JHUAPLTechnologyLicenseAgreementMember 2021-10-01 2021-10-31 0001829247 BFRG:YearTwentyTwentyThreeMember BFRG:JHUAPLTechnologyLicenseAgreementMember 2021-10-01 2021-10-31 0001829247 BFRG:YearTwentyTwentyFourMember BFRG:JHUAPLTechnologyLicenseAgreementMember 2021-10-01 2021-10-31 0001829247 BFRG:NewLicenseAgreementMember 2022-07-08 2022-07-08 0001829247 BFRG:OtherPartiesMember BFRG:NewLicenseAgreementMember 2022-07-08 0001829247 BFRG:InternallyDevelopmentDrugProjectsMember BFRG:NewLicenseAgreementMember 2022-07-08 0001829247 srt:MaximumMember BFRG:NewLicenseAgreementMember 2022-07-08 0001829247 srt:MinimumMember BFRG:NewLicenseAgreementMember 2022-07-08 0001829247 BFRG:YearTwentyTwentyTwoMember BFRG:NewLicenseAgreementMember 2022-07-08 2022-07-08 0001829247 BFRG:YearTwentyTwentyThreeMember BFRG:NewLicenseAgreementMember 2022-07-08 2022-07-08 0001829247 BFRG:YearTwentyTwentyFourMember BFRG:NewLicenseAgreementMember 2022-07-08 2022-07-08 0001829247 BFRG:NewLicenseAgreementMember 2023-05-30 2023-05-31 0001829247 BFRG:YearTwentyTwentyThreeMember BFRG:NewLicenseAgreementMember 2023-05-30 2023-05-31 0001829247 BFRG:YearTwentyTwentyFiveMember BFRG:NewLicenseAgreementMember 2023-05-30 2023-05-31 0001829247 BFRG:YearTwentyTwentySixMember BFRG:NewLicenseAgreementMember 2023-05-30 2023-05-31 0001829247 BFRG:YearTwentyTwentySevenMember BFRG:NewLicenseAgreementMember 2023-05-30 2023-05-31 0001829247 BFRG:YearTwentyTwentyTwoMember BFRG:NewLicenseAgreementMember 2023-05-30 2023-05-31 0001829247 BFRG:YearTwentyTwentyThreeMember BFRG:NewLicenseAgreementMember 2023-12-31 0001829247 BFRG:GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember 2022-01-14 0001829247 BFRG:NewLicenseAgreementMember 2023-12-31 0001829247 BFRG:NewLicenseAgreementMember 2022-12-31 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 2022-02-22 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2023-02-28 2023-02-28 0001829247 BFRG:YearTwentyTwentyThreeMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 2022-02-22 0001829247 BFRG:YearTwentyTwentyFourMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 2022-02-22 0001829247 BFRG:YearTwentyTwentyFiveMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 2022-02-22 0001829247 BFRG:YearTwentyTwentySixMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 2022-02-22 0001829247 BFRG:YearTwentyTwentySevenMember BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-02-22 2022-02-22 0001829247 BFRG:JohnsHopkinsUniversityMebendazoleLicenseMember 2022-12-31 0001829247 BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-13 0001829247 BFRG:YearTwentyTwentySevenMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-11 2022-10-13 0001829247 BFRG:YearTwentyTwentyEightMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-11 2022-10-13 0001829247 BFRG:YearTwentyTwentyNineMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-11 2022-10-13 0001829247 BFRG:YearTwentyThirtyMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-11 2022-10-13 0001829247 BFRG:YearTwentyThirtyOneMember BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-11 2022-10-13 0001829247 BFRG:JohnsHopkinsUniversityProdrugLicenseMember 2022-10-11 2022-10-13 0001829247 BFRG:LicenseAgreementMember 2023-12-31 0001829247 BFRG:LicenseAgreementMember 2022-12-31 0001829247 us-gaap:CommonStockMember us-gaap:SubsequentEventMember BFRG:SecuritiesPurchaseAgreementMember 2024-10-18 2024-10-18 0001829247 us-gaap:CommonStockMember us-gaap:SubsequentEventMember BFRG:SecuritiesPurchaseAgreementMember 2024-10-18 0001829247 BFRG:PrefundedWarrantsMember us-gaap:SubsequentEventMember BFRG:SecuritiesPurchaseAgreementMember 2024-10-18 0001829247 BFRG:CommonWarrantSharesMember us-gaap:SubsequentEventMember BFRG:SecuritiesPurchaseAgreementMember 2024-10-18 0001829247 us-gaap:SubsequentEventMember BFRG:PlacementAgentWarrantsMember 2024-10-18 2024-10-18 0001829247 us-gaap:SubsequentEventMember BFRG:PlacementAgentWarrantsMember 2024-10-18 0001829247 srt:ChiefFinancialOfficerMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001829247 us-gaap:EmployeeStockOptionMember us-gaap:RelatedPartyMember 2021-01-01 2021-12-31 0001829247 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001829247 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001829247 2021-12-01 2021-12-31 iso4217:USD shares iso4217:USD shares pure true 0001829247 S-1/A

P7Y0M29D

Amendment No. 1 BULLFROG AI HOLDINGS, INC. NV 84-4786155 325 Ellington Blvd. Unit 317 Gaithersburg MD 20878 (240) 658-6710 Vininder Singh Bullfrog AI Holdings, Inc. 325 Ellington Blvd. Unit 317 Gaithersburg MD 20878 Non-accelerated Filer true true false

4238988

2624730

358537

145882

4597525

2770612

4681

5974

4602206

2776586

91374

103656

515658

80694

172005

779037

184350

779037

184350

0.00001

5500000

73449

0.00001

100000000

7850550

6094644

18873691

12347098

-15050602

-9754924

3823169

2592236

4602206

2776586

65000

5200

59800

566584

380015

1632409

1023619

1253357

983929

3835213

3067940

1819941

1363944

5467622

4091559

-1819941

-1304144

-5467622

-4031759

4978

5758

16150

76880

-92959

61455

56924

204868

142675

56477

51166

188718

-27164

-1763464

-1252978

-5278904

-4058923

16774

-1763464

-1252978

-5295678

-4058923

-0.22

-0.21

-0.67

-0.72

8124834

6094644

7880288

5667997

73449

4021935

1341662

-4399055

-3057352

127450

1297318

7293638

7293651

7692

49999

50000

331166

1535612

1535615

-1325547

73449

5658111

10348361

-5724602

4623817

262267

436533

1494654

1494658

-1480398

73449

6094644

12105282

-7205000

4900344

121460

-1252978

73449

6094644

12226742

-8457978

3768826

73449

6094644

12347098

-9754924

2592236

335417

1247092

5674638

5674651

508814

105811

105816

16774

-16774

-1903794

73449

7850550

18479738

-11675492

6804326

192382

-1611646

73449

7850550

18672120

-13287138

5385062

73449

7850550

18672120

-13287138

5385062

201571

-1763464

73449

7850550

18873691

-15050602

3823169

73449

7850550

18873691

-15050602

3823169

-5278904

-4058923

1293

729370

511177

50000

-92959

20000

212655

337433

-12282

-433490

434964

-796865

-32000

-4338214

-4983282

5674651 7293651

105816

1494658

100000

319950

561885

697534

389880

484244

5952472

8781649

1614258

3798367

2624730

57670

4238988

3856037

16150

93916

1535615

<p id="xdx_800_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zEL9nAehZ5h4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">1. Organization and Nature of Business Description of Business Bullfrog AI Holdings, Inc. (“we”, “our” or the “Company”) was incorporated in the State of Nevada in February 2020. Bullfrog AI Holdings, Inc. is the parent company of Bullfrog AI, Inc. and Bullfrog AI Management, LLC which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. All of our operations are currently conducted through Bullfrog AI Holdings, Inc., which began operations in February 2020. We are a company focused specifically on advanced Artificial Intelligence and Machine Learning (AI/ML) driven analysis of complex data sets in medicine and healthcare. Our objective is to utilize our platform for a precision medicine approach to drug asset enablement through external partnerships and selective internal development. Most new therapeutics will fail at some point in preclinical or clinical development. These failures are the primary drivers for the high cost of developing new therapeutics. A major part of the difficulty in developing new therapeutics is efficient integration of complex and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process. Artificial Intelligence and Machine Learning (AI/ML) has emerged as a digital solution to help address this problem. We use artificial intelligence and machine learning to advance medicines for both internal and external projects. Most current AI/ML platforms still fall short in their ability to synthesize disparate, high-dimensional data for actionable insight. Our analytical platform is composed of an ensemble of state-of-the-art machine learning and artificial intelligence models. Our core platform technology, named bfLEAP™, is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics Laboratory (JHU-APL) which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise, multi-dimensional understanding of their data. We are deploying our analytical platform, including bfLEAP™, for use in several critical stages of development of internal programs and through strategic partnerships and collaborations with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need. The proprietary analytical platform utilizes both supervised and unsupervised machine learning. As such, it is able to reveal real and meaningful connections in the data without the need for a priori hypothesis. Algorithms used in the platform are designed to handle highly imbalanced data sets and successfully identify combinations of factors that are associated with outcomes of interest. Our platform leverages models that use both correlative and causative machine learning and artificial intelligence approaches which provide a comprehensive approach to predictive analysis which is expected to lead to meaningful insights including the molecular drivers of disease. In this regard, with our access to proprietary data sets such as our strategic data and commercialization agreements with the Lieber Institute for Brain Development (“LIBD”), we have increased our internal efforts on target discovery. Our goal is to improve the odds of success at all stages of pre-clinical and clinical therapeutics development for in-house programs and for our strategic partners and collaborators. Our business model includes enabling the success of ongoing clinical trials and rescuing late stage failed drugs (i.e., Phase 2 or Phase 3 clinical trial failures) by bringing them in-house for development prior to eventual divestiture; although, we also consider entering collaborations for earlier stage drugs. We pursue our drug asset enhancement business by leveraging the powerful and proven bfLEAP™ AI/ML platform initially developed at JHU-APL. We believe the bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. Liquidity and Going Concern The Company has had negative cash flows from operations and operated at a net loss since inception. In the first quarter of 2023, we completed our initial public offering (“IPO”). In February 2024, we received net proceeds of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240201__20240229__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zIEly5Kfr6Oi" title="Net proceeds from offering">5.7 million from an underwritten secondary public offering of common stock and warrants. As of September 30, 2024, the Company has a cash balance of approximately $4.2 million. In October 2024, we received net proceeds of approximately $2.7 million from a registered direct offering of common stock and pre-funded warrants, and concurrent private placement of common stock warrants. In the absence of significant revenues in 2024 and 2025, the Company believes that its capital resources are sufficient to fund planned operations into the fourth quarter of 2025. Accordingly, we will require additional capital to continue to execute our strategy. We anticipate raising this additional capital through various avenues including sales of equity securities, debt transactions, licensing agreements and collaborative arrangements. Although management believes that such funding sources will be available, there can be no assurance that any such arrangements will be consummated to provide sufficient capital when needed to allow us to continue our operations, or if available, on terms acceptable to us. If we do not raise sufficient funds in a timely manner, among other things, we may be forced to delay, scale back or eliminate some or all our research and product development programs and/or our capital expenditures or to enter into arrangements on unfavorable terms. We currently do not have commitments for future funding from any source. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. Accordingly, our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

5700000

4200000

2700000

2. Summary of Significant Accounting Policies Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Bullfrog AI Holdings, Inc. and our wholly owned subsidiaries and have been prepared in conformity with United States generally accepted accounting principles (“GAAP”) for interim financial information. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated statements are unaudited and should be read in conjunction with the consolidated financial statements and related notes included in our 2023 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2024. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with the audited annual consolidated financial statements included in Form 10-K and, in the opinion of management, include all adjustments of a normal recurring nature necessary to fairly state our financial position, our results of operations, and cash flows. The results for the nine months ended September 30, 2024 are not necessarily indicative of the operating results expected for the year ending December 31, 2024 or any other future period. In February 2023, we completed a 1-for-7 reverse split of our common stock. Stockholders’ equity and all references to shares and per share amounts in the accompanying unaudited condensed consolidated financial statements have been adjusted to reflect the reverse stock split for all periods presented. Revenue Recognition The Company recognizes revenue based on the following five step model: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of the contract with a customer</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of the performance obligations in the contract</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">This step describes how distinct performance obligations in the contract must be handled.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determination of the transaction price</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods or services to the customer.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocation of the transaction price to the performance obligations in the contract</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods or services.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognition of revenue when, or as, the Company satisfies a performance obligation</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen.</td></tr> </table> Contract Services The Company anticipates that the majority of its revenues to be recognized in the near future will result from discovery and monetization of new drug targets and intellectual property from data use partnerships focused on analysis of rich proprietary data sets. The target market for monetization will primarily be mid-size to large biopharmaceutical organizations seeking to build their new drug target pipeline. A secondary revenue channel is fee for service partnerships with biopharmaceutical companies and other organizations of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform. This platform is aimed at predicting targets of interest, patterns, relationships, anomalies, and molecular drivers of disease. The Company believes that there will be additional on-going work requested from partners; therefore, the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and, in some instances, the potential for rights to new intellectual property generated from the analysis. Once data analysis and the analysis report are complete, the Company delivers the analysis set to the customer and recognizes revenue at that point in time. Significant Accounting Policies There have been no new or material changes to the significant accounting policies discussed in the Company’s audited financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Impact of Recently Issued Accounting Standards The Company has evaluated issued Accounting Standards Updates (“ASUs”) not yet adopted and believes the adoption of these standards will not have a material impact on its consolidated financial statements.

Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Bullfrog AI Holdings, Inc. and our wholly owned subsidiaries and have been prepared in conformity with United States generally accepted accounting principles (“GAAP”) for interim financial information. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated statements are unaudited and should be read in conjunction with the consolidated financial statements and related notes included in our 2023 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 29, 2024. The unaudited condensed consolidated financial statements have been prepared on a basis consistent with the audited annual consolidated financial statements included in Form 10-K and, in the opinion of management, include all adjustments of a normal recurring nature necessary to fairly state our financial position, our results of operations, and cash flows. The results for the nine months ended September 30, 2024 are not necessarily indicative of the operating results expected for the year ending December 31, 2024 or any other future period. In February 2023, we completed a 1-for-7 reverse split of our common stock. Stockholders’ equity and all references to shares and per share amounts in the accompanying unaudited condensed consolidated financial statements have been adjusted to reflect the reverse stock split for all periods presented.

completed a 1-for-7 reverse split of our common stock

Revenue Recognition The Company recognizes revenue based on the following five step model: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of the contract with a customer</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of the performance obligations in the contract</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">This step describes how distinct performance obligations in the contract must be handled.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determination of the transaction price</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods or services to the customer.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocation of the transaction price to the performance obligations in the contract</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods or services.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognition of revenue when, or as, the Company satisfies a performance obligation</td></tr><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen.</td></tr> </table>

Contract Services The Company anticipates that the majority of its revenues to be recognized in the near future will result from discovery and monetization of new drug targets and intellectual property from data use partnerships focused on analysis of rich proprietary data sets. The target market for monetization will primarily be mid-size to large biopharmaceutical organizations seeking to build their new drug target pipeline. A secondary revenue channel is fee for service partnerships with biopharmaceutical companies and other organizations of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform. This platform is aimed at predicting targets of interest, patterns, relationships, anomalies, and molecular drivers of disease. The Company believes that there will be additional on-going work requested from partners; therefore, the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and, in some instances, the potential for rights to new intellectual property generated from the analysis. Once data analysis and the analysis report are complete, the Company delivers the analysis set to the customer and recognizes revenue at that point in time. Significant Accounting Policies There have been no new or material changes to the significant accounting policies discussed in the Company’s audited financial statements and the notes thereto included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023.

Impact of Recently Issued Accounting Standards The Company has evaluated issued Accounting Standards Updates (“ASUs”) not yet adopted and believes the adoption of these standards will not have a material impact on its consolidated financial statements.

3. Convertible Notes August 2021 Note In August 2021, the Company entered into a convertible loan agreement with an unrelated party for a commitment of up to $195,000 with a <span id="xdx_90B_ecustom--OriginalIssuanceDiscountRate_pid_dp_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zeymTPBnkO2d" title="Original issuance discount rate">5% original issue discount and a <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20210831__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zgLARAUkYPD1" title="Interest rate">9% interest rate. The loan was repaid in its entirety in February 2023. December 2021 Note In December 2021, the Company entered into a loan agreement with an unrelated party with a principal amount of $<span id="xdx_90F_eus-gaap--ProceedsFromNotesPayable_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zA2YzuMSXvXa" title="Proceeds from notes payable">25,000, a <span id="xdx_904_ecustom--OriginalIssuanceDiscountRate_pid_dp_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z1O4Rvvsr2va" title="Original issuance discount rate">10% original issue discount and a <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20211231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zzZ16DUNAlI5" title="Interest rate">6% interest rate. Concurrent with the closing of the Company’s IPO in February 2023, the note converted according to its terms into <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20211201__20211231__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zSmu0ZI0vj6j" title="Shares issued in debt conversion">6,939 shares of common stock. No gain or loss was recognized on the conversion. Convertible Bridge Notes In 2022, the Company received approximately $991,000 of gross proceeds from the issuance of Convertible Bridge Notes from several offerings. Concurrent with the closing of the Company’s IPO in February 2023, all of the Convertible Bridge Notes converted according to their terms into <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230201__20230228__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesMember_z76PB8ykNm87" title="Conversion of stock, shares">269,513 shares of common stock. No gain or loss was recognized on the conversions.

195000

0.05

0.09

25000

0.10

0.06

6939

991000

269513

4. Convertible Notes – Related Party SAFE Agreement In July 2021, the Company entered into a Simple Agreement for Future Equity (SAFE) with a related party at a purchase price of $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_c20210731__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zHNqbpcXqYw5" title="Notes payable">150,000. In February 2023, the SAFE terminated and converted into <span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230201__20230228__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember_zNZOSJkg7QT8" title="Conversion of stock, shares">32,967 shares of common stock according to its terms upon the closing of the Company’s IPO. The conversion was considered a redemption for accounting purposes and consequently, the Company recognized a $63,626 loss on the conversion. August 2021 Note In August 2021, the Company entered into a convertible loan agreement with a related party in the amount of $<span id="xdx_909_ecustom--ConvertibleNotesPayableRelatedParties_iI_c20210831__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zEosbLkYzuY3" title="Convertible notes payable related party">99,900. In February 2023, the related party elected to convert the convertible loan into <span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230201__20230228__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zltXuEEDSuq3" title="Conversion of stock, shares">21,747 shares of common stock according to its terms upon the closing of the Company’s IPO. The conversion was considered a redemption for accounting purposes and consequently, the Company recognized a $29,333 loss on the conversion.

150000

32967

63626 99900

21747

29333

5. Notes Payable In January 2023, the Company entered into a short-term note payable with a principal balance of $100,000, an original issue discount of 20% and a 9% interest rate. The note was repaid in its entirety in February 2023. In February 2023, the Company entered into an agreement to finance a portion of the premium for its Directors and Officers Insurance. The agreement provided for financing of $697,534 of the premium, repayments in 10 equal monthly installments of $71,485 each through December 2023 and accrued interest at 6.5%. The financing was repaid during 2023. In February 2024, the Company again entered into an agreement to finance a portion of the premium for its Directors and Officers Insurance. The agreement provides for financing of $561,885 of the premium, repayments in 10 equal monthly installments of $58,005 each through December 2024 and accrued interest at 6.99%.

100000

0.20

0.09

697534

repayments in 10 equal monthly installments

71485

each through December 2023

0.065

561885

repayments in 10 equal monthly installments

58005

each through December 2024

0.0699

6. Stockholder’s Equity Preferred Stock The Company has 10,000,000 shares of preferred stock authorized at a par value of $0.00001 with <span id="xdx_906_eus-gaap--PreferredStockSharesAuthorized_iI_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z5O5JuJUCHh7" title="Preferred stock, shares authorized">5,500,000 being designated as Series A Convertible Preferred Stock. Of the <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zvsQAqt5s1uf" title="Preferred stock, shares authorized">5,500,000 authorized shares of Series A Convertible Preferred Stock, <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20240930__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z5QAKvlkH557" title="Preferred stock, shares outstanding">73,449 were issued and outstanding as of September 30, 2024. Each share of Series A Convertible Preferred Stock is convertible at any time into 10 shares of the Company’s common stock. The Series A Preferred Stock is the economic equivalent of the common stock but has no voting rights and is subject to a blocker which prohibits the conversion into common stock if it would result in the investor owning more than <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20240930__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InvestorsMember__srt--RangeAxis__srt--MinimumMember_zHBhFDwGg6Ci" title="Maximum ownership percentage">4.99% of the Company’s outstanding common stock at such time. Common Stock The Company has 100,000,000 shares of common stock authorized at a par value of $0.00001. In February 2023, the Company completed its IPO for the sale of 1,297,318 units (each, a “Unit,” collectively, the “Units”) at a price of $6.50 per Unit for a total of approximately $8.4 million of gross proceeds. <span id="xdx_90C_eus-gaap--SaleOfStockDescriptionOfTransaction_c20230201__20230228__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrantsMember_zaqx0GKZ4yDa" title="Sale of stock and warrant, description">Each Unit consisted of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230228__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrantsMember_zQtOoa1ZV3E8" title="Exercise price of warrant">7.80 per share, and <span id="xdx_905_eus-gaap--SaleOfStockDescriptionOfTransaction_c20230201__20230228__us-gaap--ClassOfWarrantOrRightAxis__custom--NonTradeableWarrantsMember_zvvUPfEU23Kc" title="Sale of stock and warrant, description">one non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230228__us-gaap--ClassOfWarrantOrRightAxis__custom--NonTradeableWarrantsMember_zKek136kxivk" title="Exercise price of warrant">8.125. In connection with the completion of its IPO, the Company issued an aggregate of <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230201__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zKff4K2Fb8u3" title="Conversion of debt into stock, shares">331,166 shares of common stock upon the conversion of certain outstanding convertible debt (see Note 3 and Note 4). In connection with the IPO, in February 2023, the Company completed a <span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20230201__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsGJHjx9d1Il" title="Reverse stock split">1-for-7 reverse split of its common stock. Stockholders’ equity and all references to shares and per share amounts in the accompanying unaudited condensed consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented. In February 2023, the Company issued <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230201__20230228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zj8vDIWIsik2" title="Issuance of common stock for services, Shares">7,692 shares of common stock for consulting services and recognized $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20230201__20230228__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIxTJ3C3vcLb" title="Issuance of common stock for services">50,000 of compensation expense related to these shares. In February 2024, the Company received approximately $<span id="xdx_904_ecustom--GrossProceedsFromOffering_pn5n6_c20240201__20240229__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_z4f61IMbAHzb" title="Gross proceeds from offering">6.5 million of gross proceeds from the sale of <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20240201__20240229__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_z4OZgwTiEL29" title="Number of shares issued">1,247,092 shares of common stock, <span id="xdx_90F_ecustom--SaleOfStockNumberOfSharesIssuedInTransactions_pid_c20240201__20240229__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_zdBgbdwUbbQj" title="Pre-funded warrants issued in offering">478,429 pre-funded warrants and <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240201__20240229__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zH9K4wOIk8Ei" title="Warrants issued in offering">1,725,521 warrants (collectively the “Units”). The Units were sold at a price of $3.782 and the sale was completed via an underwritten secondary public offering and includes the underwriter’s exercise of their overallotment option. The warrants have an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zrU4Qw8Lxplb" title="Exercise price of warrant">4.16 and expire five years from issuance. The pre-funded warrants had an exercise price of $<span id="xdx_909_ecustom--ExercisePriceOfPrefundedWarrant_iI_pid_c20230224__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_z92UMpUsaNqb" title="Exercise price of the prefunded warrant">0.001 and were exercised in their entirety in the first quarter of 2024. Dilutive securities are excluded from the diluted earnings per share calculation when their effect is anti-dilutive. As of September 30, 2024, 73,449 shares of preferred stock, <span id="xdx_90D_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountWarrants_c20240101__20240930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_z3ZFOoE5TKk6" title="Number of warrants excluded from EPS calculation">5,307,444 warrants and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5nwsQ7zQ0Sj" title="Number of options excluded from EPS calculation">849,427 options for common shares were excluded from the calculation of net loss per share. As of September 30, 2023, 73,449 shares of preferred stock, <span id="xdx_901_ecustom--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountWarrants_c20230101__20230930__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zOZ2qDi4KpYf" title="Number of warrants excluded from EPS calculation">3,796,164 warrants and <span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6wrZ6Pksv3e" title="Number of options excluded from EPS calculation">507,717 options for common shares were excluded from the calculation of net loss per share. 2022 Equity Incentive Plan In November 2022, the Company’s Board of Directors adopted, and its shareholders approved, the 2022 Equity Incentive Plan (the “Plan”). The Plan provides for the granting of equity-based awards to employees, directors, and consultants. The Plan provides for equity-based awards including incentive stock options, non-qualified stock options, stock appreciation rights, performance share awards, cash awards and other equity-based awards. Awards are limited to a maximum term of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20221101__20221130__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoEquityIncentivePlanMember_zVEIxBvIhcK2" title="Original life">10 years and any exercise prices shall not be less than 100% of the fair market value of one share of common stock on the grant date. Stock Options The following tables summarizes the stock option activity for the nine months ended September 30, 2024: Schedule of Stock Options Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-Average Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-Average Remaining Contractual Term (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Aggregate Intrinsic Value</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%">Outstanding at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240930_zoktzXCdHpia" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Shares, Outstanding at Beginning">527,717</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930_zio2pOR7OXP5" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">4.17</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_ze7FvjNGFKUl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20240930_zZTt0cmIyzS2" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning">112,141</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240930_zDUZj1gYoOS4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Granted">368,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240930_zYzUx1DdIiP7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-Average Exercise Price, Granted">3.71</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20240930_zoe1x4wNjBFe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Exercised">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930_zZf0uMZRvjY9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-Average Exercise Price, Exercised"> -</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20240930_zKfiiwkCrgt3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Forfeited / canceled">(46,290</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240930_zKLfLeJHSD44" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted-Average Exercise Price, Forfeited / canceled">3.95</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding at September 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240930_zLFRfLs56qOf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Outstanding at Ending">849,427</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930_zlM5Zf1qCkR9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Ending">3.98</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zg5SbYbsaOS1" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Outstanding">8.72</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20240930_zZSBW9yXcgd8" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Ending">25,652</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Vested at September 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20240930_z0TSTwukUAsa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Vested at Ending">449,434</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20240930_zrYmSiXptsvg" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Exercise Price, Vested at Ending">4.06</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930_zUVXVoou93G8" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Vested at Ending">8.27</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20240930_zqpCPkW1dv8d" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Vested at Ending">16,837</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-Average Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-Average Remaining Contractual Term (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Aggregate Intrinsic Value</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%">Outstanding at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zEWTxjuLveSd" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Shares, Outstanding at Beginning">69,217</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930_z9WWqs31XQIc" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">3.06</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zjedNP0Ya3od" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.08</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20230930_zBAT3FGOoV2k" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning">117,669</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930_ztLnzeA2mHyl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Granted">438,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930_zo8UTjbJHkIh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-Average Exercise Price, Granted">4.41</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230930_zFwQKuxiHYg2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Exercised">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930_zq3Kh1udz3l8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-Average Exercise Price, Exercised">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230930_zf13jTHnwme" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Forfeited / canceled">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230930_zrZDjL2qZHzi" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted-Average Exercise Price, Forfeited / canceled"> -</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding at September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zyNb9fBSdfpc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Outstanding at Ending">507,717</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930_zKKERRJ8YdIi" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Ending">4.23</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zrBX4ACy4ezc" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Outstanding">9.17</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20230930_z8XOJrPCv4b" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Ending">102,441</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Vested at September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20230930_zHttZWz0Pwp5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Vested at Ending">215,623</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20230930_z31neTnCx86h" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Exercise Price, Vested at Ending">3.97</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_zAsTT2YR0ezd" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Vested at Ending">8.64</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20230930_zqtURzsUKgIk" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Vested at Ending">52,644</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zAEFFwKwdbnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The fair value of options granted during the nine months ended September 30, 2024 and 2023 was estimated using the Black-Scholes option pricing model based on the assumptions in the table below: Schedule of Black Scholes Option Pricing Model <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td> <td colspan="5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Nine Months Ended September 30,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930_zvFjmZBq4uK2" style="font-family: Times New Roman, Times, Serif">0%</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930_zFHByYwWmrG2" style="font-family: Times New Roman, Times, Serif">0%</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20240930_z76P4h5PNrV7" style="font-family: Times New Roman, Times, Serif">92% - 97%</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20230930_zkARP3bHBXPl" style="font-family: Times New Roman, Times, Serif">87% - 92%</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20240930_zy2V32Uvrfpj" style="font-family: Times New Roman, Times, Serif">3.5% - 4.4%</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20230930_zif9kZc19CMf" style="font-family: Times New Roman, Times, Serif">3.4% - 4.1%</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected life (in years)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_zY0xURhMUyt2" style="font-family: Times New Roman, Times, Serif">5.3 - 6.0</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zdzuYqucXFmc" style="font-family: Times New Roman, Times, Serif">5.0 - 6.0</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dividend yield – The Company does not expect to pay a dividend in the foreseeable future.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Volatility – The trading volatility was determined by calculating the volatility of the Company’s peer group.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Risk-free interest rate – This is the U.S. Treasury rate, having a term comparable to the expected life of the stock option.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected life of options – The expected life of options granted to employees was determined using the simplified method.</td></tr></table> The weighted-average grant-date fair value of options granted during the nine months ended September 30, 2024 and 2023 was $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20240101__20240930_zKUs4qOCQ0Y5" title="Weighted-average grant-date fair value of options granted">2.83 and $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20230930_ziNbroksYtDf" title="Weighted-average grant-date fair value of options granted">3.20, respectively. During the three and nine months ended September 30, 2024, the Company recognized $201,571 and $726,363, respectively, of compensation expense related to stock options. During the three and nine months ended September 30, 2023, the Company recognized $116,410 and $475,465, respectively, of compensation expense related to stock options. As of September 30, 2024, the total unrecognized compensation expense related to unvested stock options was approximately $1,084,000, which the Company expects to recognize over a weighted-average period of approximately <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20240101__20240930_zMsHzvQUSkZ5" title="Weighted-average period">1.5 years. Warrants The following table provides details for the Company’s outstanding warrants as of September 30, 2024: Schedule of Outstanding Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Expiration</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Warrants</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center">$0.0007</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span id="xdx_905_ecustom--WarrantExpirationPeriod_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_znIaGKlw3bu8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2030</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_zKMDQGRjb7Q5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">274,286</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zgpw9qDgahuc">2.10 - $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zHqkGgm5VtZ6">2.66</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90E_ecustom--WarrantExpirationPeriod_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zIh9sRtE21K" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026 - 2032</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember_z4yEONb5L5Rb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">446,160</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zTyFlB2PL467">3.36 - $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zyQjCbZ5IGn6">4.27</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90E_ecustom--WarrantExpirationPeriod_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zDP510xKw3E" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028 - 2029</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember_ztmRk4UG8qWd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,933,226</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zl4ucyIxQq1h">6.51 - $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zcL74Gkp31g7">7.80</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_ecustom--WarrantExpirationPeriod_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zxAn7Ft420M1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026 - 2032</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember_z8N9Q4w3RFR4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,484,829</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">$8.125</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span id="xdx_907_ecustom--WarrantExpirationPeriod_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_zB1WQ8p7KeNj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027 - 2028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember_zSENr5UzFtza" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,443,227</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,581,728</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Warrants Issued in Conjunction with Transactions During the year ended December 31, 2023, the Company issued the following warrants as part of the Company’s February 2023 IPO: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z93xzEnsbqf4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">276,452 contingent warrants to certain debt holders with an exercise price of $4.27 and an expiration date 5 years from issuance. As of September 30, 2024, 204,033 warrants have been exercised and 72,419 remain outstanding. As a result of the February 2024 secondary public offering transaction, the exercise price of the warrants was reduced to $3.782 pursuant to the anti-dilution provision contained in the warrants. The effect of the change in price was recognized as a deemed dividend of $<span id="xdx_901_ecustom--NetIncomeLossAvailableToCommonStockholdersDeemedDividend_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJXBkk3uwusb" title="Net loss available to common stockholders">5,794 which increases net loss available to common stockholders for the nine months ended September 30, 2024.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersMember_zUw0TAuTp4Fb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">18,000 contingent warrants as fees to the Company’s underwriters with an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersMember_zQRnijrXrGb3">8.125 and an expiration date <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230228__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersMember_zMrIXI9sSpv8">4 years from issuance. As of September 30, 2024, none of these warrants have been exercised. As a result of the February 2024 secondary public offering transaction, the exercise price of the warrants was reduced to $<span id="xdx_90D_eus-gaap--SaleOfStockPricePerShare_iI_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersMember_zXA0K1sNcuRj">3.782 pursuant to the anti-dilution provision contained in the warrants. The effect of the change in price was recognized as a deemed dividend of $<span id="xdx_901_eus-gaap--PreferredStockDividendsAndOtherAdjustments_c20240101__20240930__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVqdDYmTxGF2">10,980 which increases net loss available to common stockholders for the nine months ended September 30, 2024.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230228__us-gaap--StatementEquityComponentsAxis__custom--TradableWarrantMember_z1pKrBRyD432" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">1,297,318 tradable warrants with an exercise price of $7.80 and an expiration date 5 years from issuance. Through September 30, 2024, 100 warrants have been exercised.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230228__us-gaap--StatementEquityComponentsAxis__custom--NonTradableWarrantMember_zgvJlVf9AYhh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">1,297,318 non-tradable warrants with an exercise price of $8.125 and an expiration date 5 years from issuance. As of September 30, 2024, 7,500 of these warrants have been exercised and 1,289,818 remain outstanding.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--TradableWarrantMember_zUutqTKJfrU3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">153,409 tradeable warrants to our underwriters pursuant to the overallotment options with an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--TradableWarrantMember_zOa3wnbpRhk7">7.80 and an expiration date <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--TradableWarrantMember_zf7kEmaUDfa9">5 years from issuance. As of September 30, 2024, none of these warrants have been exercised.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradableWarrantMember_zAKajmPXKEg2" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">153,409 non-tradeable warrants to our underwriters pursuant to the overallotment options with an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradableWarrantMember_zHEzjsAHRw8f">8.125 and an expiration date <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradableWarrantMember_z8UNs9rOYOpj">5 years from issuance. As of September 30, 2024, none of these warrants have been exercised.</td></tr></table> During the nine months ended September 30, 2024, the Company issued the following warrants as part of the Company’s secondary public offering: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_902_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240229__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZy33xo9ziYj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">1,507,139 warrants to purchase shares of the Company’s common stock at an exercise price of $4.16 per share and an expiration date 5 years from issuance. In addition, the Company issued an additional <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUHay9MwpMuc">218,382 warrants with an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUcR0mk39F1">4.16 and an expiration date <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--TradableWarrantMember_zQfv3SxT7pp7">5 years from issuance pursuant to the underwriters’ overallotment option. As of September 30, 2024, <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zo5JNnvonwg9">16,000 of these warrants have been exercised and <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zRemEDRAHClf">1,709,521 remain outstanding.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_905_ecustom--SaleOfStockNumberOfSharesIssuedInTransactions_pid_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zBgC9r4Mm6R4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">478,429 pre-funded warrants with an exercise price of $0.001. As of September 30, 2024, all of these pre-funded warrants have been exercised.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"></td><td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_pid_c20240930__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcSdfLe5sYt3" style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">90,428 warrants with an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zKkqZjUYFYOc">4.16 per share and an expiration date <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240930__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbzpJ4vnCxe1">5 years from issuance to our underwriters. The warrants were valued at approximately $<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstanding_iI_c20240930__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwritersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQjiT41RJB5f">263,000, and as of September 30, 2024, none of these warrants have been exercised.</td></tr></table> Warrants Issued as Consideration for Services The following table summarizes the activity for warrants issued as consideration for services for the nine months ended September 30, 2024 and the year ended December 31, 2023: Schedule of Warrant Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Remaining Contractual Term (Years)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231_ztIVDfTG5zg9" style="width: 11%; text-align: right" title="Number of Warrants, Outstanding at Beginning">678,176</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zVCS8igtUKLe" style="width: 11%; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">1.57</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zdTj8JbnO9u2" style="font-family: Times New Roman, Times, Serif">7.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iS_c20230101__20231231_zMdjT7oGwGGf" style="width: 11%; text-align: right" title="Aggregate intrinsic value, beginning balance">2,131,123</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231_z0MaQwl9DMsg" style="text-align: right" title="Warrants Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231_fWzRd_zgKPsJDJyGdl" style="text-align: right" title="Weighted average exercise price, granted"> -</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231_zkNhzPJybb6e" style="text-align: right" title="Number of warrants, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisedPrice_c20230101__20231231_fWzVd_zBNzVAvPWf4h" style="text-align: right" title="Weighted average exercise price, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20231231_zWvKeM8wsYZd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_z9qYfMoZMBe4" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240930_z2dw9QbKPw1d" style="text-align: right" title="Number of Warrants, Outstanding at Beginning">678,176</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930_z7smSuWTBIn8" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">1.57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zrNR2OEzC0n4" style="font-family: Times New Roman, Times, Serif">6.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iS_c20240101__20240930_zv0ockKnlnS6" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning">1,209,136</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240930_zE6A9u37CsI1" style="text-align: right" title="Number of Warrants, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240930_fWzRd_zfiHhmjq1pQ3" style="text-align: right" title="Weighted-Average Exercise Price, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20240930_ziVKJUxUDk09" style="text-align: right" title="Number of Warrants, Exercised">(14,285</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisedPrice_c20240101__20240930_fWzVd_zNuPirxveCH9" style="text-align: right" title="Weighted-Average Exercise Price, Exercised">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20240101__20240930_zTBzA6xh4TWf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Forfeited / Canceled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240930_z669TOIdMdsi" style="padding-bottom: 1pt; text-align: right" title="Weighted-Average Exercise Price, Forfeited / canceled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240930_zCX0WpIYJdfd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding at Ending">663,891</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930_z4Pb9HXdBpC6" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Ending">1.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zACGJ3kD6Hxf" style="font-family: Times New Roman, Times, Serif">5.8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iE_c20240101__20240930_zWjiAtBlx59j" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Ending">964,513</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingNumber_iE_c20240101__20240930_zA0q7DYx0LGg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Vested at Ending">663,891</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930_z2nDuoJXU22d" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Exercise Price, Vested at Ending">1.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zH96s8rPlNSa" style="font-family: Times New Roman, Times, Serif">5.8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20240101__20240930_zibysR9EqMZc" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Vested at Ending">964,513</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the three and nine months ended September 30, 2024, the Company recognized $<span id="xdx_907_ecustom--ShareBasedCompensationExpensesRelatedToWarrants_c20240701__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwq34qWE2y8i" title="Compensation expense related to warrants">0 and $<span id="xdx_904_ecustom--ShareBasedCompensationExpensesRelatedToWarrants_c20240101__20240930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbUzP5RMmRt4" title="Compensation expense related to warrants">3,007, respectively, of compensation expense related to certain warrants. During the three and nine months ended September 30, 2023, the Company recognized $<span id="xdx_90A_ecustom--ShareBasedCompensationExpensesRelatedToWarrants_c20230701__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr0la5ooORw2" title="Compensation expense related to warrants">5,050 and $<span id="xdx_90F_ecustom--ShareBasedCompensationExpensesRelatedToWarrants_c20230101__20230930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zVKdH7LCMbw2" title="Compensation expense related to warrants">35,712, respectively, of compensation expense related to certain warrants. As of September 30, 2024, there was <span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_do_c20240930__us-gaap--StatementEquityComponentsAxis__custom--UnvestedWarrantsMember_zAwDfMy13sod" title="Unrecognized compensation expense">no unrecognized compensation expense related to unvested warrants.

10000000

0.00001

5500000

73449

0.0499

100000000

0.00001

1297318

6.50

8400000

Each Unit consisted of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $7.80 per share

7.80

one non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $8.125.

8.125

331166

1-for-7 reverse split

7692

50000

6500000

1247092

478429

1725521

3.782

4.16

0.001

73449

5307444

849427

73449

3796164

507717

P10Y

The following tables summarizes the stock option activity for the nine months ended September 30, 2024: Schedule of Stock Options Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-Average Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-Average Remaining Contractual Term (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Aggregate Intrinsic Value</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%">Outstanding at December 31, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20240101__20240930_zoktzXCdHpia" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Shares, Outstanding at Beginning">527,717</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930_zio2pOR7OXP5" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">4.17</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_ze7FvjNGFKUl" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.00</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20240101__20240930_zZTt0cmIyzS2" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning">112,141</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20240101__20240930_zDUZj1gYoOS4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Granted">368,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240930_zYzUx1DdIiP7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-Average Exercise Price, Granted">3.71</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20240101__20240930_zoe1x4wNjBFe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Exercised">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20240101__20240930_zZf0uMZRvjY9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-Average Exercise Price, Exercised"> -</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20240101__20240930_zKfiiwkCrgt3" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Forfeited / canceled">(46,290</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20240101__20240930_zKLfLeJHSD44" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted-Average Exercise Price, Forfeited / canceled">3.95</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding at September 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20240101__20240930_zLFRfLs56qOf" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Outstanding at Ending">849,427</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930_zlM5Zf1qCkR9" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Ending">3.98</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zg5SbYbsaOS1" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Outstanding">8.72</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20240101__20240930_zZSBW9yXcgd8" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Ending">25,652</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Vested at September 30, 2024</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20240930_z0TSTwukUAsa" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Vested at Ending">449,434</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20240930_zrYmSiXptsvg" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Exercise Price, Vested at Ending">4.06</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240101__20240930_zUVXVoou93G8" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Vested at Ending">8.27</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20240930_zqpCPkW1dv8d" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Vested at Ending">16,837</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Shares</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-Average Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-Average Remaining Contractual Term (Years)</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Aggregate Intrinsic Value</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 40%">Outstanding at December 31, 2022</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20230930_zEWTxjuLveSd" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Number of Shares, Outstanding at Beginning">69,217</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20230930_z9WWqs31XQIc" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">3.06</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zjedNP0Ya3od" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.08</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20230930_zBAT3FGOoV2k" style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning">117,669</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Granted</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20230930_ztLnzeA2mHyl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Granted">438,500</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20230930_zo8UTjbJHkIh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-Average Exercise Price, Granted">4.41</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Exercised</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20230930_zFwQKuxiHYg2" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Exercised">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20230930_zq3Kh1udz3l8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted-Average Exercise Price, Exercised">-</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20230930_zf13jTHnwme" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Forfeited / canceled">-</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20230930_zrZDjL2qZHzi" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right" title="Weighted-Average Exercise Price, Forfeited / canceled"> -</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Outstanding at September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20230930_zyNb9fBSdfpc" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Outstanding at Ending">507,717</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20230930_zKKERRJ8YdIi" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Ending">4.23</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20230930_zrBX4ACy4ezc" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Outstanding">9.17</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20230930_z8XOJrPCv4b" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Ending">102,441</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Vested at September 30, 2023</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20230930_zHttZWz0Pwp5" style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Vested at Ending">215,623</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20230930_z31neTnCx86h" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Exercise Price, Vested at Ending">3.97</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20230930_zAsTT2YR0ezd" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Vested at Ending">8.64</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20230930_zqtURzsUKgIk" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Vested at Ending">52,644</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

527717

4.17

P9Y

112141

368000

3.71

46290

3.95

849427

3.98

P8Y8M19D

25652

449434

4.06

P8Y3M7D

16837

69217

3.06

P7Y29D

117669

438500

4.41

507717

4.23

P9Y2M1D

102441

215623

3.97

P8Y7M20D

52644

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zAEFFwKwdbnd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The fair value of options granted during the nine months ended September 30, 2024 and 2023 was estimated using the Black-Scholes option pricing model based on the assumptions in the table below: Schedule of Black Scholes Option Pricing Model <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td> <td colspan="5" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Nine Months Ended September 30,</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2024</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2023</td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: left">Expected dividend yield</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20240101__20240930_zvFjmZBq4uK2" style="font-family: Times New Roman, Times, Serif">0%</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20230930_zFHByYwWmrG2" style="font-family: Times New Roman, Times, Serif">0%</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected volatility</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20240101__20240930_z76P4h5PNrV7" style="font-family: Times New Roman, Times, Serif">92% - 97%</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20230930_zkARP3bHBXPl" style="font-family: Times New Roman, Times, Serif">87% - 92%</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Risk-free interest rate</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20240101__20240930_zy2V32Uvrfpj" style="font-family: Times New Roman, Times, Serif">3.5% - 4.4%</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20230930_zif9kZc19CMf" style="font-family: Times New Roman, Times, Serif">3.4% - 4.1%</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Expected life (in years)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20240101__20240930__srt--RangeAxis__srt--MinimumMember_zY0xURhMUyt2" style="font-family: Times New Roman, Times, Serif">5.3 - 6.0</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20230930__srt--RangeAxis__srt--MinimumMember_zdzuYqucXFmc" style="font-family: Times New Roman, Times, Serif">5.0 - 6.0</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> </table>

0.92

0.97

0.87

0.92

0.035

0.044

0.034

0.041

P5Y3M18D

P6Y

P5Y

P6Y

2.83

3.20

201571

726363

116410

475465

1084000

P1Y6M

The following table provides details for the Company’s outstanding warrants as of September 30, 2024: Schedule of Outstanding Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Exercise Price</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Expiration</td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of Warrants</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center">$0.0007</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span id="xdx_905_ecustom--WarrantExpirationPeriod_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_znIaGKlw3bu8" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2030</td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: right"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceMember_zKMDQGRjb7Q5" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">274,286</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zgpw9qDgahuc">2.10 - $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zHqkGgm5VtZ6">2.66</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90E_ecustom--WarrantExpirationPeriod_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zIh9sRtE21K" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026 - 2032</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember_z4yEONb5L5Rb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">446,160</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zTyFlB2PL467">3.36 - $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zyQjCbZ5IGn6">4.27</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90E_ecustom--WarrantExpirationPeriod_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zDP510xKw3E" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2028 - 2029</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember_ztmRk4UG8qWd" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,933,226</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">$<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zl4ucyIxQq1h">6.51 - $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zcL74Gkp31g7">7.80</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_901_ecustom--WarrantExpirationPeriod_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zxAn7Ft420M1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026 - 2032</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember_z8N9Q4w3RFR4" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,484,829</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt">$8.125</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1pt"><span id="xdx_907_ecustom--WarrantExpirationPeriod_c20240101__20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_zB1WQ8p7KeNj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027 - 2028</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20240930__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember_zSENr5UzFtza" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,443,227</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,581,728</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

0.0007

2030

274286

2.10

2.66

2026 2032

446160

3.36

4.27

2028 2029

1933226

6.51

7.80

2026 2032

1484829

8.125

2027 2028

1443227

5581728

276452

4.27

P5Y

204033

72419

3.782

5794

18000

8.125

P4Y

3.782

10980

1297318

7.80

P5Y

100

1297318

8.125

P5Y

7500

1289818

153409

7.80

P5Y

153409

8.125

P5Y

1507139

4.16

P5Y

218382

4.16

P5Y

16000

1709521

478429

0.001

90428

4.16

P5Y

263000

The following table summarizes the activity for warrants issued as consideration for services for the nine months ended September 30, 2024 and the year ended December 31, 2023: Schedule of Warrant Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Remaining Contractual Term (Years)</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231_ztIVDfTG5zg9" style="width: 11%; text-align: right" title="Number of Warrants, Outstanding at Beginning">678,176</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zVCS8igtUKLe" style="width: 11%; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">1.57</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zdTj8JbnO9u2" style="font-family: Times New Roman, Times, Serif">7.6</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iS_c20230101__20231231_zMdjT7oGwGGf" style="width: 11%; text-align: right" title="Aggregate intrinsic value, beginning balance">2,131,123</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231_z0MaQwl9DMsg" style="text-align: right" title="Warrants Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231_fWzRd_zgKPsJDJyGdl" style="text-align: right" title="Weighted average exercise price, granted"> -</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231_zkNhzPJybb6e" style="text-align: right" title="Number of warrants, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisedPrice_c20230101__20231231_fWzVd_zBNzVAvPWf4h" style="text-align: right" title="Weighted average exercise price, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20231231_zWvKeM8wsYZd" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_z9qYfMoZMBe4" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, forfeited">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2023</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20240101__20240930_z2dw9QbKPw1d" style="text-align: right" title="Number of Warrants, Outstanding at Beginning">678,176</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20240101__20240930_z7smSuWTBIn8" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">1.57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zrNR2OEzC0n4" style="font-family: Times New Roman, Times, Serif">6.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iS_c20240101__20240930_zv0ockKnlnS6" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning">1,209,136</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20240101__20240930_zE6A9u37CsI1" style="text-align: right" title="Number of Warrants, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20240101__20240930_fWzRd_zfiHhmjq1pQ3" style="text-align: right" title="Weighted-Average Exercise Price, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20240101__20240930_ziVKJUxUDk09" style="text-align: right" title="Number of Warrants, Exercised">(14,285</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisedPrice_c20240101__20240930_fWzVd_zNuPirxveCH9" style="text-align: right" title="Weighted-Average Exercise Price, Exercised">2.66</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20240101__20240930_zTBzA6xh4TWf" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Forfeited / Canceled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20240101__20240930_z669TOIdMdsi" style="padding-bottom: 1pt; text-align: right" title="Weighted-Average Exercise Price, Forfeited / canceled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20240101__20240930_zCX0WpIYJdfd" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding at Ending">663,891</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930_z4Pb9HXdBpC6" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Ending">1.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_904_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zACGJ3kD6Hxf" style="font-family: Times New Roman, Times, Serif">5.8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iE_c20240101__20240930_zWjiAtBlx59j" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Ending">964,513</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested at September 30, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingNumber_iE_c20240101__20240930_zA0q7DYx0LGg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Vested at Ending">663,891</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20240101__20240930_z2nDuoJXU22d" style="padding-bottom: 2.5pt; text-align: right" title="Weighted-Average Exercise Price, Vested at Ending">1.55</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20240930_zH96s8rPlNSa" style="font-family: Times New Roman, Times, Serif">5.8</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20240101__20240930_zibysR9EqMZc" style="padding-bottom: 2.5pt; text-align: right" title="Aggregate Intrinsic Value, Vested at Ending">964,513</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

678176

1.57 P7Y7M6D 2131123

678176

1.57 P6Y7M6D 1209136

14285

2.66

663891

1.55 P5Y9M18D 964513 663891 1.55 P5Y9M18D 964513 0 3007 5050 35712

7. Income Taxes The Company has not recorded any tax provision or benefit for the nine months ended September 30, 2024 and 2023. The Company has provided a valuation allowance for the full amount of its net deferred tax assets since realization of any future benefits from deductible temporary differences, net operating loss carryforwards, and research and development credits are not more-likely-than-not to be realized at September 30, 2024 and December 31, 2023.

8. Material Agreements JHU-APL Technology License In February 2018, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL. The license covers three (3) issued patents, one (1) new provisional patent application, non-patent rights to proprietary libraries of algorithms and other trade secrets, as well as modifications and improvements. In October 2021, the Company executed an amendment to the original license for improvements and new advanced analytics capabilities. In consideration of the rights granted to the Company under the License Agreement, JHU received a warrant equal to five percent (<span id="xdx_909_ecustom--PercentageOfWarrantIssued_iI_pid_dp_uPure_c20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember_zrP5dMoTLkDe" title="Warrant issuance percentage">5%) of the then fully diluted equity base of the Company, which was diluted following the closing of the IPO. Under the terms of the License Agreement, JHU will be entitled to an eight percent (<span id="xdx_90E_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember_zZHQycl6Tjac" title="Royalty percent on net sales">8%) royalty on net sales for the services provided by the Company as well as fifty percent (<span id="xdx_905_ecustom--SublicensePercentage_iI_pid_dp_uPure_c20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember_zN2TM7iIJFIe" title="Percentage of sublicense revenues">50%) of all sublicense revenues received by the Company on services and sublicenses in which the JHU licensed technology was utilized. In addition, the Company is required to pay JHU an annual maintenance fee of $1,500. Minimum annual royalty payments are $20,000 for 2022, $80,000 for 2023, and $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_z6D5vkg6B9fj" title="Royalty payments for 2024">300,000 per year for 2024 and beyond. If cumulative annual royalty payments do not reach these levels, the amount due to JHU to reach the annual minimum is due by January 1st of the following year. Failure to make annual royalty payments is considered a material breach under the agreement and upon notice from JHU of a material breach, the Company shall have 60 days to cure the material breach. In July 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the additional technology developed to enhance the bfLEAP™ platform. The new license provides additional intellectual property rights including patents, copyrights, and knowhow to be utilized under the Company’s bfLEAP™ analytical AI/ML platform. This license supersedes the previous license. In consideration of the new license, the Company issued 39,879 shares of common stock to JHU. Under the terms of the new License Agreement, JHU will be entitled to eight percent (<span id="xdx_902_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220731__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--OtherPartiesMember_zyrqsBIYA9y9" title="Royalty percent">8%) of net sales for the services provided by the Company to other parties and three percent (<span id="xdx_903_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220731__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--InternallyDevelopmentDrugProjectsMember_zjzJj0CvtjR4" title="Royalty percent">3%) for internally developed drug projects in which the JHU license was utilized. The new license also contains tiered sub licensing fees that start at 50% and reduce to <span id="xdx_906_ecustom--IncreaseDecreaseInSublicensePercentageBasedOnRevenues_iI_pid_dp_uPure_c20220731__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zDH3YA0lCvM5" title="Sublicense fee based on revenue">25% based on revenues. In addition, under the new license agreement, the minimum annual royalty payments are $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoYearMember_z4rpd8eszivi" title="Royalty payments">30,000 for 2022, $<span id="xdx_907_eus-gaap--RoyaltyExpense_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyThreeYearMember_z11sc49CLIm3" title="Royalty payments">80,000 for 2023, and $<span id="xdx_905_eus-gaap--RoyaltyExpense_c20220701__20220731__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFourYearAndBeyondMember_z202ZGNHSPsa" title="Royalty payments">300,000 per year for 2024 and beyond. In May 2023, the Company and JHU-APL entered into Amendment number 1 of the July 2022 License Agreement whereby the Company gained access to certain improvements including additional patents and knowhow in exchange for a series of payments totaling $<span id="xdx_90D_eus-gaap--FiniteLivedPatentsGross_iI_c20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardTypeAxis__custom--FromTwoThousandAndTwentyThreeThroughTwoThousandAndTwentySevenMember_zOOFAPTQekx1" title="License payments">275,000. The first of these payments for $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20230501__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--JulyTwoThousandTwentyThreeMember_zzuPfffc4eL9" title="Royalty payments">75,000 was paid in July 2023 and the remaining payments of $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20230501__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveYearMember_zASNEuafRQl5" title="Royalty payments">75,000, $<span id="xdx_903_eus-gaap--RoyaltyExpense_c20230501__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySixYearMember_zXZpAuhUKWll" title="Royalty payments">75,000, and $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20230501__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySevenYearMember_zbWBh5paxWy6" title="Royalty payments">50,000 are due in years 2025, 2026, and 2027, respectively. The amendment also reduced the 2023 minimum annual royalty payment to $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20230501__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyThreeYearMember_zzKdFGZgJ4c6" title="Royalty payments">60,000, all other financial terms remain the same. As of September 30, 2024, we have accrued $<span id="xdx_902_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFourYearMember_zAGxGZ52JEc8" title="Accrued royalty payments">225,000 of the 2024 minimum annual royalty payments. George Washington University - Beta2-spectrin siRNA License In January 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from George Washington University (GWU) for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma (HCC). The license covers methods claimed in three US and worldwide patent applications, and also includes use of this approach for treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. In consideration of the rights granted to the Company under the License Agreement, the Company paid GWU a $20,000 License Initiation Fee. Under the terms of the License Agreement, GWU will be entitled to a three percent (<span id="xdx_904_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220131__us-gaap--TypeOfArrangementAxis__custom--GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember_zfmeiOCGCvA6" title="Royalty percent">3%) royalty on net sales subject to quarterly minimums once the first sale has occurred subsequent to regulatory approval, as well sublicense or assignment fees in the event the Company sublicenses or assigns their rights to use the technology. The Company will also reimburse GWU for previously incurred and ongoing patent costs. The Sublicense and Assignment fee amounts decline as the Company advances the clinical development of the licensed technology. The license agreement also contains milestone payments for clinical development through the approval of an NDA and commercialization. As of September 30, 2024, there has been <span id="xdx_90A_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember_zySPxySrHaoe" title="Accrued royalty expenses">no accrual for royalties since we have not begun to generate applicable revenue. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely. Johns Hopkins University – Mebendazole License In February 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) for the use of an improved formulation of Mebendazole for the treatment of any human cancer or neoplastic disease. This formulation shows potent activity in animal models with different types of cancer and has been evaluated in a Phase I clinical trial in patients with high-grade glioma (NCT01729260). The trial, an open-label dose-escalation study, assessed the safety and efficacy of the improved formulation with adjuvant temozolomide in 24 patients with newly diagnosed gliomas. Investigators observed no dose-limiting toxicity in patients receiving all but the highest tested dose (200mg/kg/day). Four of the 15 patients receiving the maximum tested dose of 200mg/kg/day experienced dose-limiting toxicity, all of which were reversed by decreasing or eliminating the dose given. There were no serious adverse events attributed to Mebendazole at any dose during the trial. 41.7% of patients who received Mebendazole were alive at two years after enrollment, and 25% were alive at four years (Gallia et al., 2021). The license covers six (6) issued patents and one (1) pending application. In consideration of the rights granted to the Company under the License Agreement, JHU will receive a staggered Upfront License Fee of $250,000. The Company initially paid $<span id="xdx_909_eus-gaap--PaymentsForFees_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zX0WqQbwmlJ4" title="License fee payment made prior to IPO">50,000 and the remaining balance of $<span id="xdx_90F_ecustom--PaymentsForLicenceFeesAfterIPO_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zwiUTVCNKj2" title="License fee payment made after IPO">200,000 was paid after the Company completed its IPO. The Company will also reimburse JHU for previously incurred and ongoing patent costs. Under the terms of the License Agreement, JHU will be entitled to three and one-half percent (<span id="xdx_90B_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220228__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zKyDSvAzt9p8" title="Royalty percent">3.5%) royalty on net sales by the Company in which the JHU license was utilized. In addition, the Company is required to pay JHU minimum annual royalty payments of $<span id="xdx_905_eus-gaap--RoyaltyExpense_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyTwoYearMember_z73m6Gwn3bDh" title="Royalty payments">5,000 for 2022, $<span id="xdx_90D_eus-gaap--RoyaltyExpense_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyThreeYearMember_zPh04GxoYM97" title="Royalty payments">10,000 for 2023, $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFourYearMember_zGuZ2VyVnck5" title="Royalty payments">20,000 for 2024, $<span id="xdx_909_eus-gaap--RoyaltyExpense_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyFiveYearMember_zUfcD8CAJmCd" title="Royalty payments">30,000 for 2025, and $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySixYearMember_z17F9mDYbHy4" title="Royalty payments">50,000 for 2026 and each year after until the first commercial sale, after which, the annual minimum royalty shall be $<span id="xdx_90F_eus-gaap--PaymentsForRoyalties_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_ziXKGqShf3L2" title="Annual minimum royalty payment">250,000. The license agreement also contains milestone payments for clinical development steps through the approval of an NDA and commercialization. As of September 30, 2024 and December 31, 2023, the balance of accrued expense related to this license agreement was $<span id="xdx_906_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_c20240930__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zOlAIJGaKLsl" title="Accrued royalty expenses">15,000 and $<span id="xdx_90D_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zwsFf9UvdH88" title="Accrued royalty expenses">10,000, respectively. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely. Johns Hopkins University – Prodrug License In October 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences for rights to commercialize N-substituted prodrugs of Mebendazole that demonstrate improved solubility and bioavailability. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications. In consideration for the rights granted to the Company under the License Agreement, JHU and IOCB will receive a staggered upfront license fee of $100,000. The Company will also reimburse JHU and IOCB for previously incurred patent costs. Under the terms of the License Agreement, JHU and IOCB will be entitled to four percent (4.0%) royalty on net sales by the Company in which the JHU and IOCB license was utilized. In addition, the Company is required to pay JHU and IOCB minimum annual royalty payments of $<span id="xdx_90F_eus-gaap--RoyaltyExpense_c20221001__20221031__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySixYearMember_zHgSN7zduGli" title="Royalty payments">5,000 for 2026, $<span id="xdx_905_eus-gaap--RoyaltyExpense_c20221001__20221031__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentySevenYearMember_zmGMt7sT158g" title="Royalty payments">10,000 for 2027, $<span id="xdx_90F_eus-gaap--RoyaltyExpense_c20221001__20221031__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyEightYearMember_zzVGVJBzdMG3" title="Royalty payments">20,000 for 2028, $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20221001__20221031__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--TwoThousandTwentyNineYearMember_z9G9WqBNhtMa" title="Royalty payments">30,000 for 2029, and $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20221001__20221031__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--TwoThousandThirtyYearMember_z0j4SJIcWMKb" title="Royalty payments">50,000 for 2030 and each year after until the first commercial sale, after which, the annual minimum royalty shall be $<span id="xdx_90A_eus-gaap--PaymentsForRoyalties_c20221001__20221031__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember_zmALnnhGxYGf" title="Annual minimum royalty payment after first commercial sale">150,000. The license agreement also contains milestone payments for patent grants, clinical development steps through the approval of an NDA and commercialization. No expenses have been accrued as of any of the periods presented. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely. 0.05 0.08 0.50

1500

20000

80000

300000

39879

0.08 0.03 0.50 0.25

30000

80000

300000

275000

75000

50000

60000

225000

20000 0.03 250000

50000

200000 0.035

5000

10000

20000

30000

50000

250000

15000

10000

100000 0.040

5000

10000

20000

30000

50000

150000

9. Subsequent Events The Company evaluates subsequent events and transactions that occur after the balance sheet date up to the date that the unaudited condensed consolidated financial statements are issued. Other than as disclosed in this Note 9 and as may be disclosed elsewhere in the notes to the accompanying unaudited condensed consolidated financial statements, there have been no subsequent events that require adjustment or disclosure in the accompanying unaudited condensed consolidated financial statements. On October 18, 2024, the Company entered into a securities purchase agreement with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue to the Purchasers, in a registered direct offering, (i) <span id="xdx_904_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20241018__20241018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zzg2tT55V5ic">862,602 shares of the Company’s common stock (the “Shares”), par value $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20241018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zbn18cIT9Tzb">0.00001 per share (“Common Stock”), pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zYgVMNAEdS55">702,398 shares of Common Stock (the “Pre-funded Warrants Shares”) with an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zelQ7pDB0Hn8">0.0001 per share, at a purchase price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_c20241018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zhpN7gHWKvK">2.00 per share of Common Stock and a purchase price of $<span id="xdx_907_eus-gaap--SharesIssuedPricePerShare_iI_c20241018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zTzduMOmHpNi">1.9999 per Pre-Funded Warrant, and (ii) in a concurrent private placement, warrants (the “Common Warrants”) to purchase an aggregate of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantSharesMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zZBIFHj4cHqg">1,565,000 shares of Common Stock (the “Common Warrant Shares”) with an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20241018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__custom--CommonWarrantSharesMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zHhgLn5tLubc">2.00 per share, which are exercisable after six (6) months from the date of issuance for a five-year period from the initial exercise date. The transaction closed on October 21, 2024, with the Company earning gross proceeds of approximately $<span id="xdx_90E_ecustom--GrossProceedsFromIssuanceOfCommonStock_pn4n6_c20241018__20241018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zJaG9ybFk45d" title="Earnings gross proceeds">3.13 million, and net proceeds of approximately $<span id="xdx_90B_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20241018__20241018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zo8ImQ8uGfCl">2.7 million. Concurrently with the securities purchase agreement, on October 18, 2024, the Company also entered into a placement agency agreement with WallachBeth Capital, LLC, as the placement agent (the “Placement Agent”), pursuant to which the Company agreed to pay <span id="xdx_907_ecustom--SaleOfSecuritiesDescription_c20241018__20241018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentWarrantsMember_z3bcQxQA5yUf" title="Sale of securities, description">the Placement Agent an aggregate cash fee of 8.0% of the gross proceeds from the sale of securities in the transaction, reimburse for certain out-of-pocket expenses, and issue to the Placement Agent (or its designees) warrants to purchase an aggregate of <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20241018__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PlacementAgentWarrantsMember_zXtRWT5Bw6U9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62,600 shares of Common Stock, equal to 4% of the aggregate number of shares of Common Stock and/or Pre-Funded Warrants sold in the registered direct offering, at an exercise price per share equal to $2.00, which is equal to the exercise price of the Common Warrants. The placement agent warrants are exercisable six (6) months from the date of issuance and expire on the five-year anniversary of initial exercise date.

862602

0.00001

702398

0.0001

2.00

1.9999

1565000

2.00

3130000

2700000

the Placement Agent an aggregate cash fee of 8.0% of the gross proceeds from the sale of securities in the transaction, reimburse for certain out-of-pocket expenses, and issue to the Placement Agent (or its designees) warrants to purchase an aggregate of

62600

2624730

57670

145882

15000

2770612

72670

5974

7699

2776586

80369

103656

543993

80694

982988

32000

1323890

254850

184350

3137721

184350

3137721

0.00001

5500000

73449

0.00001

100000000

6094644

4021935

12347098

1341662

-9754924

-4399055

2592236

-3057352

2776586

80369

65000

10000

65000

10000

5200

800

5200

800

59800

9200

1432614

609270

3994710

1855731

5427324

2465001

-5367524

-2455801

79089

347145

-92959

183703

459

11655

-346686

-5355869

-2802487

-0.89

-0.70

6049819

4009852

4622789

587415

-1596568

-1009107

9221

340152

-11097 -11097

205984

226136

226138

112225

-1

39879

189828

73449

-734492

-7

-2802487

73449

4021935

1341662

-4399055

-3057352

73449

4021935

1341662

-4399055

-3057352

631533

1297318

7293638

7293651

7692

49999

50000

331166

1535612

1535615

436533

1494654

1494658

-5355869

73449

6094644

12347098

-9754924

2592236

73449

6094644

12347098

-9754924

2592236

-5355869

-2802487

1725

1045

631533

340152

189828

50000

-92959

20000

214429

-9221

130882

15000

-440337

475399

-838428

373273

281250

-32000

22000

-6001299

-910890

8744

-8744

7293651

1494658

1016290

100000

319950

49000

697534

8568359

967290

2567060

47656

57670

10014

2624730

57670

93916

5757

11097

1535615

226138

<p id="xdx_803_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zDKUEgRiU3Z6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">1. Organization and Nature of Business Description of Business Bullfrog AI Holdings, Inc. (“we”, “our” or the “Company”) was incorporated in the State of Nevada on February 6, 2020. Bullfrog AI Holdings, Inc. is the parent company of Bullfrog AI, Inc. and Bullfrog AI Management, LLC which were incorporated in Delaware and Maryland, in 2017 and 2021, respectively. All of our operations are currently conducted through BullFrog AI Holdings, Inc., which began operations on February 6, 2020. We are a company focused specifically on advanced AI/ML-driven analysis of complex data sets in medicine and healthcare. Our objective is to utilize our platform for precision medicine approach to drug asset enablement through external partnerships and selective internal development. Most new therapeutics will fail at some point in preclinical or clinical development. This is the primary driver of the high cost of developing new therapeutics. A major part of the difficulty in developing new therapeutics is efficient integration of complex and highly dimensional data generated at each stage of development to de-risk subsequent stages of the development process. Artificial Intelligence and Machine Learning (AI/ML) has emerged as a digital solution to help address this problem. We use artificial intelligence and machine learning to advance medicines for both internal and external projects. Most current AI/ML platforms still fall short in their ability to synthesize disparate, high-dimensional data for actionable insight. Our platform technology, named, bfLEAP™ is an analytical AI/ML platform developed at The Johns Hopkins University Applied Physics Laboratory (JHU-APL) which is able to surmount the challenges of scalability and flexibility currently hindering researchers and clinicians by providing a more precise, multi-dimensional understanding of their data. We are deploying bfLEAP™ for use at several critical stages of development for internal programs and through strategic partnerships and collaborations with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may otherwise not receive the therapies they need. The bfLEAP™ platform utilizes both supervised and unsupervised machine learning – as such, it is able to reveal real/meaningful connections in the data without the need for a priori hypothesis. Algorithms used in the bfLEAP™ platform are designed to handle highly imbalanced data sets to successfully identify combinations of factors that are associated with outcomes of interest. Our primary goal is to improve the odds of success at any stage of pre-clinical and clinical therapeutics development, for in house programs, and our strategic partners and collaborators. Our primary business model is enabling the success of ongoing clinical trials or rescue of late stage failed drugs (i.e., Phase 2 or Phase 3 clinical trial failures) for development and divestiture; although, we will also consider collaborations for earlier stage drugs. We hope to accomplish this through strategic acquisitions of current clinical stage and failed drugs for in-house development, or through strategic partnerships with biopharmaceutical industry companies. We are able to pursue our drug asset enhancement business by leveraging a powerful and proven AI/ML platform (trade name: bfLEAP™) initially developed at JHU-APL. We believe the bfLEAP™ analytics platform is a potentially disruptive tool for analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational R&D and clinical trial settings. Liquidity and Going Concern The Company has had negative cash flows from operations and operated at a net loss since inception. In the first quarter of 2023, we completed our initial public offering (“IPO”). In February 2024 the Company received net proceeds of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zxSUTbD0Kdo2" title="Net proceeds from offering">4.9 million dollars from an underwritten public offering of <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_ze8S2qunC6ml" title="Shares issued in offering">1,507,139 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_z3g4NUNhszz3" title="Warrants to purhcase common stock">1,507,139 shares of common stock at an offering price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zurD6ok5Vz84" title="Offering price per share">3.782. The <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dtY_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zfwfmAS4XOh9" title="Warrants term">5 year warrants have an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_z3SSx56hWps5" title="Exercise price of warrant">4.16. On February 21, 2024, the underwriters elected to take an overallotment of <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240221__20240221__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_za6b3jUzTzwc" title="Number of shares issued">218,382 common shares and the Company received net proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20240221__20240221__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zs1Vym8tDh68" title="Net proceeds from share issuance">750,000. In the absence of significant revenues in 2024 the Company believes that its capital resources are sufficient to fund planned operations for more than 12 months from the date of this filing.

4900000

1507139

3.782

P5Y

4.16

218382

750000

2. Summary of Significant Accounting Policies Basis of Presentation The accompanying consolidated financial statements include the accounts of Bullfrog AI Holdings, Inc. and our wholly owned subsidiaries and have been prepared in conformity with United States generally accepted accounting principles (“GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. On February 13, 2023, we completed a 1-for-7 reverse split of our common stock. Stockholders’ equity and all references to shares and per share amounts in the accompanying consolidated financial statements have been adjusted to reflect the reverse stock split for all periods presented. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates include, but are not limited to, revenue recognition, allowances for doubtful accounts, recoverability of deferred tax assets and certain other of our accrued liabilities. Actual results could differ from these estimates. Revenue Recognition The Company recognizes revenue based on the following five step model: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of the contract with a customer</td></tr></table> This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of the performance obligations in the contract</td></tr></table> This step describes how distinct performance obligations in the contract must be handled. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determination of the transaction price</td></tr></table> This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocation of the transaction price to the performance obligations in the contract</td></tr></table> This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognition of revenue when, or as, the Company satisfies a performance obligation</td></tr></table> Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen. Contract Services The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis. Once data analysis and the analysis report are complete, the Company delivers the analysis set to the customer and recognizes revenue at that point in time. Financial Instruments The carrying value of short-term instruments, including cash and cash equivalents, accounts payable and accrued expenses approximate fair value due to the relatively short period to maturity for these instruments. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a three-level valuation hierarchy for disclosures of fair value measurements, defined as follows: Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value. The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis. Cash The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. As of December 31, 2023 and 2022, cash balances were $2,624,730 and $57,670, respectively. Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management. Cost of Sales Cost of sales is comprised of royalties and the cost of outsourced services provided to the Company related to customer service contracts. Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives. Advertising The Company follows the policy of charging the costs of advertising to expense as incurred. Income Taxes Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized. The Company recognizes a tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by taxing authorities. Interest and penalties associated with such uncertain tax positions are classified as a component of income tax expense. Stock-Based Compensation Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period. Net Loss per Share We calculate basic net loss per share by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by giving effect to all potentially dilutive common stock equivalents in the period, including unvested stock options and warrants. As we have reported losses for all periods presented, all potentially dilutive securities have been excluded from the calculation of diluted net loss per share as their effect would be antidilutive. Recent Accounting Pronouncements Impact of Recently Issued Accounting Standards In December 2023, the FASB issued ASU No. 2024-09: Income Taxes (Topic 740): Improvements to Income Tax Disclosures that requires entities to disclose additional information about federal, state, and foreign income taxes primarily related to the income tax rate reconciliation and income taxes paid. The new standard also eliminates certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The guidance is effective for our fiscal year ending December 31, 2025. The guidance does not affect recognition or measurement in our consolidated financial statements. The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.

Basis of Presentation The accompanying consolidated financial statements include the accounts of Bullfrog AI Holdings, Inc. and our wholly owned subsidiaries and have been prepared in conformity with United States generally accepted accounting principles (“GAAP”). All intercompany accounts and transactions have been eliminated in consolidation. On February 13, 2023, we completed a 1-for-7 reverse split of our common stock. Stockholders’ equity and all references to shares and per share amounts in the accompanying consolidated financial statements have been adjusted to reflect the reverse stock split for all periods presented.

completed a 1-for-7 reverse split of our common stock

Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates include, but are not limited to, revenue recognition, allowances for doubtful accounts, recoverability of deferred tax assets and certain other of our accrued liabilities. Actual results could differ from these estimates.

Revenue Recognition The Company recognizes revenue based on the following five step model: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of the contract with a customer</td></tr></table> This step outlines the criteria that must be met when establishing a contract with a customer to supply goods or services. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Identification of the performance obligations in the contract</td></tr></table> This step describes how distinct performance obligations in the contract must be handled. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Determination of the transaction price</td></tr></table> This step outlines what must be considered when establishing the transaction price, which is the amount the business expects to receive for transferring the goods and services to the customer. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Allocation of the transaction price to the performance obligations in the contract</td></tr></table> This step outlines guidelines for allocating the transaction price across the contract’s separate performance obligations, and is what the customer agrees to pay for the goods and services. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Recognition of revenue when, or as, the Company satisfies a performance obligation</td></tr></table> Revenue can be recognized as the business meets each performance obligation. This step specifies how that should happen.

Contract Services The Company anticipates that the majority of revenues to be recognized in the near future will result from our fee for service partnership offering, designed for biopharmaceutical companies, as well as other organizations, of all sizes that have challenges analyzing data throughout the drug development process. The Company provides the customer with an analysis of large complex data sets using the Company’s proprietary Artificial Intelligence / Machine Learning platform called bfLEAP™. This platform is designed to predict targets of interest, patterns, relationships, and anomalies. The Company believes that there will be additional on-going work requested from partners therefore the service model utilizes a master services agreement with work or task orders issued for discrete analysis performed at the discovery, preclinical, or clinical stages of drug development. The Company receives a cash fee and in some instances the potential for rights to new intellectual property generated from the analysis. Once data analysis and the analysis report are complete, the Company delivers the analysis set to the customer and recognizes revenue at that point in time.

Financial Instruments The carrying value of short-term instruments, including cash and cash equivalents, accounts payable and accrued expenses approximate fair value due to the relatively short period to maturity for these instruments. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a three-level valuation hierarchy for disclosures of fair value measurements, defined as follows: Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value. The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.

Cash The Company considers cash to consist of cash on hand and temporary investments having an original maturity of 90 days or less that are readily convertible into cash. As of December 31, 2023 and 2022, cash balances were $2,624,730 and $57,670, respectively.

2624730

57670

Concentrations of Credit Risk The Company’s financial instruments that are exposed to a concentration of credit risk are cash and accounts receivable. Occasionally, the Company’s cash in interest-bearing accounts may exceed FDIC insurance limits. The financial stability of these institutions is periodically reviewed by senior management.

Cost of Sales Cost of sales is comprised of royalties and the cost of outsourced services provided to the Company related to customer service contracts.

Property and Equipment Property and equipment are stated at cost. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition is reflected in earnings. For financial statement purposes, property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives.

Advertising The Company follows the policy of charging the costs of advertising to expense as incurred.

Income Taxes Deferred income tax assets and liabilities are determined based on the estimated future tax effects of net operating loss and credit carry forwards and temporary differences between the tax basis of assets and liabilities and their respective financial reporting amounts measured at the current enacted tax rates. The Company records an estimated valuation allowance on its deferred income tax assets if it is not more likely than not that these deferred income tax assets will be realized. The Company recognizes a tax benefit from an uncertain tax position if it is more likely than not that the tax position will be sustained on examination by taxing authorities. Interest and penalties associated with such uncertain tax positions are classified as a component of income tax expense.

Stock-Based Compensation Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.

Net Loss per Share We calculate basic net loss per share by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by giving effect to all potentially dilutive common stock equivalents in the period, including unvested stock options and warrants. As we have reported losses for all periods presented, all potentially dilutive securities have been excluded from the calculation of diluted net loss per share as their effect would be antidilutive.

Recent Accounting Pronouncements Impact of Recently Issued Accounting Standards In December 2023, the FASB issued ASU No. 2024-09: Income Taxes (Topic 740): Improvements to Income Tax Disclosures that requires entities to disclose additional information about federal, state, and foreign income taxes primarily related to the income tax rate reconciliation and income taxes paid. The new standard also eliminates certain existing disclosure requirements related to uncertain tax positions and unrecognized deferred tax liabilities. The guidance is effective for our fiscal year ending December 31, 2025. The guidance does not affect recognition or measurement in our consolidated financial statements. The Company does not believe that any other recently issued effective pronouncements, or pronouncements issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.

3. Property and Equipment Property and equipment consisted of $8,744 of equipment and has accumulated depreciation of $2,770 and $1,045, as of December 31, 2023 and 2022, respectively. Depreciation expense totaled $1,725 and $1,045 in the years ended December 31, 2023 and 2022, respectively.

8744

2770

1045

1725

1045

4. Convertible Notes March 2020 Note On March 27, 2020, the Company entered into a convertible loan agreement with the Maryland Technology Development Corporation with a principal balance of $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20200327__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zySK5SRhzb5i" title="Principal balance">200,000 at <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200327__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zks7OFeDHgYa" title="Interest rate">6% interest. The maturity date of the loan was <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20200327__20200327__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zVIBJlQtLPT5" title="Principal balance">September 27, 2021. During the year ended December 31, 2022, the full amount of the loan and interest totaling $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220101__20221231__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zE4g1bWxOYFf" title="Debt converted">226,138 was converted into <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220101__20221231__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zR44KCWv5EXe" title="Shares issued in debt conversion">205,984 shares of common stock of the Company, in accordance with the conversion notice submitted by the noteholder. Pursuant to the note agreement, the number of shares that the note converted into was based on the note balance plus accrued interest, divided by $<span id="xdx_905_ecustom--FullyDilutedEquity_iI_c20200327__dei--LegalEntityAxis__custom--MarylandTechnologyDevelopmentCorporationMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember_zoTj03FCMmsa" title="Fully diluted equity">5,000,000, times the fully diluted equity of the company, excluding convertible securities issued for capital raising purposes. There was no gain or loss due to conversion being within the terms of the agreement. August 2021 Note In August 2021, the Company entered into a convertible loan agreement with an unrelated party for a commitment of up to $<span id="xdx_903_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20210831__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zZJVEl8qO6Jh" title="Principal balance">195,000 with a <span id="xdx_90A_ecustom--OriginalIssuanceDiscountRate_dp_uPure_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zg18PkkmEXH5" title="Original issuance discount rate">5% original issue discount and a <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20210831__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zWsFJCbSkFWa" title="Interest rate">9% interest rate. The loan provided for a maturity date of <span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zwNAVXYioh32" title="Maturity Date">February 9, 2022. We borrowed $<span id="xdx_908_eus-gaap--ProceedsFromNotesPayable_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zm6RLck4oaO" title="Proceeds from notes payable">72,000 and $<span id="xdx_90C_eus-gaap--ProceedsFromNotesPayable_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zvxaVceLroo2" title="Proceeds from notes payable">123,000 of principal in the years ended December 31, 2021 and 2022, respectively. The noteholder had the right to convert the principal and interest into common shares of the Company at the IPO at a<span id="xdx_906_ecustom--ConversionDiscountRate_dp_c20210801__20210831__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zWCovlhk8sF9" title="Conversion discount rate"> 20% discount to the IPO price. As of December 31, 2022, the loan was outstanding with a principal balance of $<span id="xdx_900_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zCAvaZmooAQ" title="Loan principal amount outstanding">195,000 and accrued interest of $<span id="xdx_906_eus-gaap--InterestPayableCurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zQ06MTyD3Fgl" title="Accrued interest">35,078. The loan was paid in its entirety in February 2023. In connection with the convertible loan agreement, the Company also issued <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zAlzbxXAZiY4" title="Warrants issued">195,000 Warrants with an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zg8oevQjfXOk" title="Exercise price">1.00 exercisable for <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20221231__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zfcJtWL3kdz3" title="Warrants term">five years from issuance. In May 2022, the Company and the note holder agreed to cancel and void the warrants and enter into a new agreement for <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220531__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zP0xx4FEqqO6" title="Warrants issued">225,000 warrants with an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220531__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zdi5ODhS3115" title="Exercise price">2.50. The Company assessed the differences in fair value and determined that they were de minimis and expensed the full value of the new warrants. December 2021 Note On December 20, 2021, the Company entered into a loan agreement with an unrelated party. The loan provided for a <span id="xdx_900_eus-gaap--DebtInstrumentMaturityDate_c20211220__20211220__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zP6EmvjcNYB9" title="Maturity date">December 19, 2022 maturity, a <span id="xdx_90D_ecustom--OriginalIssuanceDiscountRate_dp_c20211220__20211220__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zGuI57VQYCRi" title="Original issuance discount rate">10% original issue discount and a <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20211220__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zCSbA4xpH56b" title="Interest rate">6% interest rate. The Company received $<span id="xdx_907_eus-gaap--ProceedsFromNotesPayable_c20211220__20211220__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zGj5NuJstvxf" title="Proceeds from notes payable">25,000 of proceeds from this note. The note was automatically convertible into shares of common stock at a discount to the IPO price or based on the valuation of the Company, whichever was more favorable to the holder. Initially, the loan was estimated to be issued with <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211220__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_z2ixijVWjwvi" title="Warrants issued">355,114 warrants. Subsequent to the closing of the loan agreement, the Company enhanced the terms of the Bridge Note Offering under which the loan was closed and in April 2022 closed on the sale of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromNotesPayable_pn6n6_c20220401__20220430__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zsrYXFMYzRb6" title="Proceeds from notes payable">1 million in face value of convertible bridge notes. Pursuant to the enhanced terms, the warrants were issued concurrently with the conversion of the note. Concurrent with the closing of the Company’s IPO, the note converted according to its terms into <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20211220__20211220__us-gaap--TypeOfArrangementAxis__custom--LoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zjtObNCoYrc5" title="Shares issued in debt conversion">6,939 shares of common stock. No gain or loss was recognized on the conversion. Convertible Bridge Notes On April 11, 2022, the Company entered into an Exclusive placement agent and/or underwriter agreement with WallachBeth Capital LLC in connection with a proposed private and/or public offerings by the Company. On April 28, 2022, the Company received approximately $775,000 of proceeds, net of approximately $91,000 of fees and a <span id="xdx_909_ecustom--OriginalIssuanceDiscountRate_dp_uPure_c20220428__20220428__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember_zmxKmrkslSP5" title="Original issuance discount rate">10% original issue discount from the sale of Convertible Bridge Notes and Warrants to several institutional investors and several individual accredited investors. In addition, the Company also received $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20220428__20220428__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWQZEjFCeMta" title="Sale of stock value">100,000 from the sale of a Convertible Bridge Note and Warrants to a related party earlier in April. In September 2022, the Company received an additional $<span id="xdx_909_eus-gaap--ProceedsFromNotesPayable_c20220901__20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zX43IR9ie5Ug" title="Proceeds from notes payable">25,000 of proceeds, net of a <span id="xdx_900_ecustom--OriginalIssuanceDiscountRate_dp_uPure_c20220901__20220930__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesAndWarrantsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zvtoL6YeSqbd" title="Original issuance discount rate">10% original issue discount from the sale of an additional Convertible Bridge Note and Warrant to an unrelated party. The Convertible Bridge Notes were initially convertible at the IPO at a 20% discount to the IPO price. The Convertible Bridge Notes provided for an original maturity date of October 31, 2022. In connection with the Convertible Bridge Notes, the purchasers were also entitled to conditional warrants to be issued upon completion of the Company’s IPO. The agreement provided for the warrants to be exercisable for a period of five years from issuance at an exercise price equal to 110% of the IPO price or, if the Company failed to complete the IPO before October 22, 2022, 90% of the IPO price. In the fourth quarter of 2022, the Company amended the Convertible Bridge Notes to (a) extend the maturity date until December 31, 2022, (b) provide that the conversion right would include interest through November 30, 2022, with interest accruing beyond that date being paid in cash and (c) revise the conversion price to be $4.27 based on a $25 million Company valuation. Concurrent with the closing of the Company’s IPO in February 2023, all of the Convertible Bridge Notes converted according to their terms into <span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230228__20230228__us-gaap--DebtInstrumentAxis__custom--ConvertibleBridgeNotesMember_zZsr2TqVGiy7" title="Shares issued in debt conversion">269,513 shares of common stock. No gain or loss was recognized on the conversion.

200000

0.06

2021-09-27

226138

205984

5000000

195000

0.05

0.09

2022-02-09

72000

123000

0.20

195000

35078

195000

1.00

P5Y

225000

2.50

2022-12-19

0.10

0.06

25000

355114

1000000

6939

775000

91000

0.10

100000

25000

0.10 0.20

2022-10-31

The agreement provided for the warrants to be exercisable for a period of five years from issuance at an exercise price equal to 110% of the IPO price or, if the Company failed to complete the IPO before October 22, 2022, 90% of the IPO price

4.27

269513

5. Convertible Notes – Related Party SAFE Agreement On July 8, 2021, the Company entered into a Simple Agreement for Future Equity (SAFE), with a related party, at a purchase price of $<span id="xdx_908_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20210708__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zpxJqabYNfIl" title="Convertible notes payable">150,000. The SAFE provided for no interest and terminated after conversion upon completion of the Company’s IPO. The SAFE provided for automatic conversion into the number of shares of SAFE Preferred Stock equal to the Purchase Amount divided by the Conversion Price, defined as either: (1) the SAFE Price (the price per share equal to the Post-Money Valuation Cap divided by the Company Capitalization) or (2) the Discount Price (the price per share of the Standard Preferred Stock sold in the Equity Financing multiplied by the Discount Rate),whichever calculation results in a greater number of shares of SAFE Preferred Stock. In February 2023, the SAFE terminated and converted into <span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230228__20230228__us-gaap--TypeOfArrangementAxis__custom--SimpleAgreementForFutureEquityMember_zqYgc4Mqazag" title="Conversion of stock, shares">32,967 shares of common stock according to its terms upon the Company’s closing of its IPO. The conversion was considered a redemption for accounting purposes and consequently, the Company recognized a $63,626 loss on the conversion. As of December 31, 2022, the $150,000 received from the SAFE was recorded at 6% imputed interest. August 2021 Note On August 19, 2021, the Company entered into a convertible loan agreement with a related party, with a principal balance of $<span id="xdx_901_eus-gaap--ConvertibleNotesPayableCurrent_iI_c20210819__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWVDmUNLzPtf" title="Convertible notes payable">99,900, an original issuance discount of <span id="xdx_908_ecustom--OriginalIssuanceDiscountRate_pid_dp_uPure_c20210818__20210819__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zWv0wdVCaFFc" title="Original issuance discount rate">5% and a <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210819__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztcq8WYhqhtg" title="Interest rate">9% interest rate. The loan provided for a maturity date of February 19, 2022. The noteholder had the right to convert the principal and interest into common shares of the Company at a conversion price based on a discount to the IPO price. In February 2023, the related party elected to convert the convertible loan into <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230228__20230228__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z8j2FvpxC2Zi" title="Conversion of stock, shares">21,747 shares of common stock according to its terms upon the Company’s closing of its IPO. The conversion was considered a redemption for accounting purposes and consequently, the Company recognized a $<span id="xdx_903_ecustom--GainLossOnDebtConversion_iN_di_c20230228__20230228__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zBVcj6gqCwU3" title="Loss on conversion">29,333 loss on the conversion. In connection with the convertible loan agreement, the Company also issued <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230228__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z8t4TgbBWA7a" title="Number of warrant shares">99,000 warrants with an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230228__us-gaap--TypeOfArrangementAxis__custom--ConvertibleLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zHTbhtWzxwb2" title="Warrant exercise price per share">1.00 exercisable for five years from issuance. In May 2022, the Company and the note holder agreed to cancel and void previous warrants and enter into a new agreement for <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20220531__us-gaap--TypeOfArrangementAxis__custom--NewLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zG4ASJt5HEij" title="Number of warrant shares">115,185 warrants with an exercise price of $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20220531__us-gaap--TypeOfArrangementAxis__custom--NewLoanAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zF9Ge2TvZit8" title="Warrant exercise price per share">2.50. The Company assessed the differences in fair value and determined that they were de minimis and expensed the full value of the new warrants.

150000

32967

63626

150000

0.06

99900

0.05

0.09

21747

-29333

99000

1.00

115185

2.50

6. Related Party During the year ended December 31, 2023, the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20230101__20231231__srt--TitleOfIndividualAxis__srt--ChiefFinancialOfficerMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zIZ8rjFRiCL1" title="Stock option services">75,000 stock options to its Chief Financial Officer for services rendered. During the year ended December 31, 2021, the Company issued <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zcInffpozRJf" title="Options issued for services">29,286 common stock options to related parties for services rendered. The options have an original life of <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjiCO94S3NYf" title="Original life">10 years and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_dtY_c20210101__20211231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSp6ONieSPh4" title="Options vesting description">vest over different periods for up to 24 months. During the years ended December 31, 2023 and 2022, the Company recognized $1,707 and $1,803, respectively of stock-based compensation related to these options. At various times in 2021, the Company entered into unsecured short term loan agreements with a related party for an aggregate principal balance of $49,000, each with a one-year maturity date, accruing interest at 5% and imputing an additional 1% interest. The full amount of the loans and interest was repaid in 2022.

75000

29286

P10Y

vest over different periods for up to 24 months

1707

1803

49000

0.05

0.01

7. Notes Payable In January 2023 the Company entered into a short-term note payable with a principal balance of $100,000, an original discount of 20% and a 9% interest rate. The note was paid in its entirety in February 2023. In February 2023, the Company entered into an agreement to finance a portion of the premium for its Directors and Officers Insurance. The agreement provides for financing of $697,534 of the premium, repayments in 10 equal monthly installments of $71,485 each through December 2023 and accrued interest at 6.5%. The financing was repaid during 2023.

100000

0.20

0.09

697534

repayments in 10 equal monthly installments

71485

0.065

8. Stockholders’ Equity Stockholder’s Equity Preferred Stock The Company has 10,000,000 shares of preferred stock authorized at a par value of $0.00001 with <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zOLV2Lkco553" title="Preferred stock, shares authorized">5,500,000 being designated as Series A Convertible Preferred Stock. On October 5, 2022, the Company entered into an exchange agreement with an Investor providing for the exchange of <span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_c20221004__20221005__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zmlCn7Iu3dl7" title="Conversion of convertible securities, shares">734,492 shares of commons stock into <span id="xdx_904_eus-gaap--ConversionOfStockSharesConverted1_c20221004__20221005__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zGeTumM2mwA6" title="Conversion of convertible securities, shares">73,449 shares of Series A Convertible Preferred Stock. Each share of Series A Convertible Preferred Stock is convertible at any time into <span id="xdx_90D_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_c20221005__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zpcuZR3qUXD8" title="Common stock issuable on conversion">10 shares of the Company’s common stock. The Series A Preferred Stock is the economic equivalent of the common stock but has no voting rights and is subject to a blocker which prohibits the conversion into common stock if it would result in the Investor owning more than <span id="xdx_90C_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20221005__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--InvestorsMember__srt--RangeAxis__srt--MinimumMember_zDUoGoXrbwOl" title="Equity method investment, ownership percentage">4.99% of the Company’s outstanding common stock at such time. The Company evaluated the terms of the exchange and determined there was no significant change in fair value and therefore the Series A Preferred Stock was valued at $<span id="xdx_901_eus-gaap--PreferredStockValue_iI_c20221005__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zBKay9ydIPX6" title="Preferred stock value">315,000 which is the Investor’s basis in the common stock that was exchanged. Common Stock The Company has 100,000,000 shares of common stock authorized at a par value of $0.00001. During the year ended December 31, 2022, the Company: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Exchanged <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--ExchangeAgreementMember_zUOkxhd8HTnl" title="Conversion of convertible securities, shares">734,429 shares of common stock for shares of Series A Convertible Preferred stock as noted above,</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Issued 205,984 shares of common stock pursuant to a conversion of $226,138 worth of convertible notes principal and interest, </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Cancelled <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--PriorAgreementsAndNewAgreementsMember_zPXJJOwiixTh" title="Shares cancelled">112,225 shares of common stock as the change in number of shares issued as part of the cancellation of the prior agreements and new agreements with advisors, and </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20221231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5aMvsOy3Ne" title="Number of shares issued">39,879 shares of common stock pursuant to a license agreement valued at $189,828. </td></tr></table> After the Company signed two licenses for two drug programs from universities in the first half of 2022 it engaged an independent valuation firm to perform an Enterprise-Equity valuation. The results of this engagement resulted in an increase in the value per share of common stock used in the Black Scholes option pricing model employed to value the Company’s equity grants and warrant issuances. In February 2023, the Company completed its IPO for the sale of 1,297,318 units (each, a “Unit,” collectively, the “Units”) at a price of $6.50 per Unit for a total of approximately $8.4 million of gross proceeds. Each Unit consisted of one share of the Company’s common stock, one tradeable warrant (each, a “Tradeable Warrant,” collectively, the “Tradeable Warrants”) to purchase one share of common stock at an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230228__us-gaap--ClassOfWarrantOrRightAxis__custom--TradeableWarrantsMember_zlW46Uhxxwqi" title="Exercise price of warrant">7.80 per share, and one non-tradeable warrant (each, a “Non-tradeable Warrant,” collectively, the “Non-tradeable Warrants”; together with the Tradeable Warrants, each, a “Warrant,” collectively, the “Warrants”) to purchase one share of the Company’s common stock at an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230228__us-gaap--ClassOfWarrantOrRightAxis__custom--NonTradeableWarrantsMember_zMgvKZCc3CK2" title="Exercise price of warrant">8.125. In connection with the completion of its IPO, the Company issued an aggregate of <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230201__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zd5eKJgWeNXi" title="Shares issued in conversion of debt">331,166 shares of common stock upon the conversion of certain outstanding convertible debt. In connection with the IPO, in February 2023, the Company completed a <span id="xdx_90A_eus-gaap--StockholdersEquityReverseStockSplit_c20230201__20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmDEd1JzHWp" title="Reverse stock split">1-for-7 reverse split of our common stock. Stockholders’ equity and all references to shares and per share amounts in the accompanying consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented. In February 2023, the Company issued 7,692 shares of common stock for consulting services and recognized $50,000 of compensation expense related to these shares. In the second quarter of 2023, we issued 436,533 shares of common stock following the exercise of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20230401__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zgjtBQVt9A0c" title="Warrant exercised">436,533 warrants for proceeds of $1,494,658. Dilutive securities are excluded from the diluted earnings per share calculation because their effect is anti-dilutive. As of December 31, 2023 and December 31, 2022, <span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zpkkFWe1VE9g" title="Number of warrants">3,521,880 and <span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zguPUUcSR5id" title="Number of warrants">927,373 warrants were not included in the calculation of net loss per share, respectively. In addition, <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAbuhhiiacug" title="Number of options">527,717 and <span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMisbaMi7X22" title="Antidilutive securities">69,217 options for common shares were not included in the calculation of net loss per share, respectively. 2022 Equity Incentive Plan In November 2022, the Company’s Board of Directors adopted, and its shareholders approved the 2022 Equity Incentive Plan (the “Plan”). The Plan provides for the granting of equity-based awards to employees, directors, and consultants. The Plan provides for equity-based awards including incentive stock options, non-qualified stock options, stock appreciation rights, performance share awards, cash awards and other equity-based awards. Awards are limited to a maximum term of <span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20221101__20221130__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zCiy5bMisUu8" title="Award period">10 years and any exercise prices shall not be less than 100% of the fair market value of one share of common stock on the grant date. The Plan authorizes an initial maximum number of shares underlying awards of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20221130__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zI1FVtP4ZG48" title="Award authorized under the plan">900,000 with an automatic annual <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_dp_c20221101__20221130__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_z4sJQpwpa5I2" title="Increased payment award, percentage">15% increase beginning in 2024. As of December 31, 2023, there were <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentyTwentyTwoEquityIncentivePlanMember_zDNCQtLgXE2c" title="Award authorized but unissued">441,500 awards authorized but unissued available under the Plan. Stock Options The following tables summarizes the stock option activity for the years ended December 31, 2023 and 2022: Schedule of Stock Options Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted-Average Remaining Contractual Term (Years)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zsuHvAmpdELg" style="width: 11%; text-align: right" title="Number of Shares, Outstanding at Beginning">468,571</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zs5PmbZrVzR5" style="width: 11%; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">3.32</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zgZt5YxQ5F0e" title="Weighted-Average Remaining Contractual Term (Years), Outstanding">7.4</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231_zJXpHQCfVG3c" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zBntGRxfUvrl" style="text-align: right" title="Number of Shares, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zCnMorcpvCFk" style="text-align: right" title="Weighted-Average Exercise Price, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zeCj1zmvRCri" style="text-align: right" title="Number of Shares, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_z3NIiK5JkPM2" style="text-align: right" title="Weighted-Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231_zXIBJxc5eu7j" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeited / canceled">(399,354</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_zGnhALYR3tAe" style="padding-bottom: 1pt; text-align: right" title="Weighted-Average Exercise Price, Forfeited / canceled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zSfKekbHwti1" style="text-align: right" title="Number of Shares, Outstanding at Beginning">69,217</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zIxeA20Lv9Xd" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">3.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dxL_c20220101__20221231_zlRaFTM3UDYi" style="text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Outstanding::XDX::P7Y0M29D">7.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValues_iS_c20230101__20231231_z7wXrWVk0g5c" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_zcsYg3u3KHhf" style="text-align: right" title="Number of Shares, Granted">458,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zGRV3rP07XB6" style="text-align: right" title="Weighted-Average Exercise Price, Granted">4.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231_zq43BleDPXwj" style="text-align: right" title="Number of Shares, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231_zudJwxIwOxr9" style="text-align: right" title="Weighted-Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231_z1suHHybeDh4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeited / canceled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231_zyOtM4zQi4pa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Forfeited / canceled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_zKq0rizFxeja" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Outstanding at Ending">527,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_zyxeINC0iPTj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Ending">4.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231_ztlTJXPxAQU9" title="Weighted-Average Remaining Contractual Term (Years), Outstanding">9.0</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20231231_zMmsS8HeZ1U8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Ending">112,141</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20231231_ztfBP9XesUeg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Vested at Ending">255,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20231231_z15m19kiaonl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Vested at Ending">4.01</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zaZlnUJgUfkk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Vested at Ending">8.5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20231231_z5Vqu4syE1E6" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested at Ending">62,193</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The fair value of options granted in the year ended December 31, 2023 was estimated using the Black-Scholes option pricing model based on the assumptions in the table below: Schedule of Black Scholes Option Pricing Model <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Expected dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: center">0%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_zSLFaZjtj5g7" title="Expected volatility, minimum">87% - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_z1Z629kaWfL1" title="Expected volatility, maximum">92%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_ze04FeNnL9Lb" title="Risk-free interest rate, minimum">3.4% - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_zd4kFfYos6P1" title="Risk-free interest rate, maximum">4.4%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z3p1QdSVk2N7" title="Expected life (in years)">5.0 - <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zxmyBnyRL8Vk" title="Expected life (in years)">6.0 </td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Volatility - The trading volatility was determined by calculating the volatility of the Company’s peer group.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected life of options – The expected life of options granted to employees was determined using the simplified method.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Risk-free interest rate – This is the U.S. Treasury rate, having a term comparable to the expected life of the stock option.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dividend yield – The Company does not expect to pay a dividend in the foreseeable future.</td></tr></table> The weighted-average grant-date fair value of options granted during the year ended December 31, 2023 was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20230101__20231231_z4TntNdG4K06" title="Weighted-average grant-date fair value of options granted">3.15. The total grant-date fair value of options granted and vested during the year ended December 31, 2023 was approximately $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20230101__20231231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zMj30wWC61X3" title="Fair value of options vested and outstanding">1,445,200 and $<span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20220101__20221231__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember_zIDlOMhwhbFa" title="Fair value of options granted and vested">585,500, respectively. No options were exercised in any of the periods presented. During the years ended December 31, 2023 and 2022, the Company recognized $592,268 and $2,010, respectively of compensation expense related to stock options. As of December 31, 2023, the total unrecognized compensation expense related to unvested stock options, was approximately $861,000, which the Company expects to recognize over a weighted-average period of approximately <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231_zwqEv5fHGcKi" title="Weighted-average recognition period">1.9 years. Warrants During the years ended December 31, 2023 and 2022, the Company granted a total of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR27vgnZFuE1" title="Share based compensation granted">3,195,906 and <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuWqLIYgn9Z2" title="Share based compensation granted">415,247 warrants, respectively. The warrants have an original life of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmTiYUFCqfY6" title="Original life">ten years and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbjwxS3LXUXf" title="Vesting description">vest over varying periods up to 24 months from the grant date. During the year ended December 31, 2023, warrants to purchase <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlEYK1U46Sp6" title="Warrants shares vested">27,867 shares vested and had a fair value of $<span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znkwK3jmbq8l" title="Intrinsic value">39,265. During the year ended December 31, 2022, <span id="xdx_904_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedNumberOfShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjyeFPNZGnO9" title="Warrants shares vested">350,908 shares of warrants vested and amended with a fair value of $<span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedIntrinsicValue_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAXW5O4cmIIe" title="Fair value value of warrants vested">337,269, 51,941 shares of warrants were reclassified with a fair value of $11,097, and <span id="xdx_90C_ecustom--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsForfeited_iI_c20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zL62gIhUoWQh" title="Warrant shares, forfeited">42,057 shares of warrants with a fair value of $1,883 were forfeited. During the year ended December 31, 2021, the Company granted a total of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z9UUmGwQKycj" title="Share based compensation granted">431,659 warrants. Of this amount, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AdvisorsMember_zKY3QhqLHhN9" title="Share based compensation granted">200,000 warrants, with a fair value of $<span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstanding_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--TitleOfIndividualAxis__custom--AdvisorsMember_zNLHzMdPqBTk" title="Fair value of warrants">12,462, were granted to advisors related to the Company’s IPO objective. The warrants have an original life of five years and vest 30 days before the intended IPO. During the year ended December31, 2021, <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zO1QJ4QsoPgf" title="Warrants shares vested">0 shares of these warrants were vested. As of June 30, 2022, the warrants for <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20220630__20220630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zN54zDLcEfxa" title="Warrant cancelled">200,000 shares were cancelled and voided per agreement of the warrant holder and the Company. There was no gain or loss recognized due to this cancellation. During the year ended December 31, 2021, the Company issued <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleBridgeDebtAgreementsMember_zCggIpFCi0Q2">92,859 warrants with a fair value of $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleBridgeDebtAgreementsMember_zNZYOsWURUgj">12,980, in connection with convertible bridge debt agreements with multiple parties including a related party. The warrants had an original life of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--ConvertibleBridgeDebtAgreementsMember_zoRglPngFVCg" title="Warrants and rights outstanding term">five years. During the period ending June 30, 2022, the Company determined that 50,735 warrants, with a fair value of $11,097, should not have been issued. The fair value was reclassified to additional paid in capital. In May 2022, the Company and the noteholders agreed to cancel and void the previous 99,000 warrants and entered into a new agreement for <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zTg1iGrZKAi1">115,185 warrants and the exercise price increased to $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_z3lLKi1gK5pe">2.50 from $1.00, with a fair value of $<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220531__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zbGLROIjerQ8">15,412. In May 2022, the Company and the note holders agreed to cancel and void the previous 195,000 warrants and entered into a new agreement for <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220531__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zqNQOaL7BHKh">225,000 warrants with an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220531__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zITKDc1fs3h7">2.50, with a fair value of $<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_c20220531__us-gaap--StatementEquityComponentsAxis__custom--WarrantOneMember__us-gaap--TypeOfArrangementAxis__custom--NewAgreementsMember_zgQhhGlUIdY3">64,978. The 92,859 warrants discussed above were initially discounted against the notes, subsequent to the year ended December 31, 2021, they were deemed voided and these individuals were issued new warrants in accordance with the new terms as stated above. We assessed the differences in fair values and determined the values were de minimis and expensed the full value of the new warrants. During the year ended December 31, 2023, the Company issued the following warrants: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In February 2023, in connection with the completion of the initial public offering, the Company issued <span id="xdx_908_ecustom--ClassOfWarrantOrRightIssued_iI_pid_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DebtHoldersMember_zvwQFk5H8c75" title="Additional shares issued">276,452 contingent warrants to certain debt holders with an exercise price of $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DebtHoldersMember_zKC8P1G3ApSe" title="Issue price per share">4.27 and an expiration date <span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DebtHoldersMember_z1IrApurKX23">5 years from issuance.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In February 2023, in connection with the completion of the initial public offering, the Company issued <span id="xdx_90E_ecustom--ClassOfWarrantOrRightIssued_iI_pid_c20230228__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwritersMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zftW8h8Gzmt5" title="Additional shares issued">18,000 contingent warrants as fees to the Company’s underwriters with an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwritersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzh98b8inhX" title="Issue price per share">8.125 and an expiration date <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnderwritersMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqZwwPxxeOxc">4 years from issuance. </td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As part of the sale of units in the Company’s initial public offering the Company issued <span id="xdx_90A_ecustom--ClassOfWarrantOrRightIssued_iI_pid_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--TradeableWarrantsMember_zmsNolLiUWZf" title="Additional shares issued">1,297,318 tradable warrants with an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--TradeableWarrantsMember_zI9uPmtgiDz2" title="Issue price per share">7.80 and an expiration date <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--TradeableWarrantsMember_zAJ7FZYRRrb2" title="Expiration term">5 years from issuance. Also, as part of the sale of units in the Company’s initial public offering, the Company issued <span id="xdx_90B_ecustom--ClassOfWarrantOrRightIssued_iI_pid_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradeableWarrantsMember_zho7tNB5CR3j" title="Additional shares issued">1,297,318 non-tradable warrants with an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradeableWarrantsMember_zxXDERDXOle8" title="Issue price per share">8.125 and an expiration date <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradeableWarrantsMember_znqBCvCCLqe9" title="Expiration term">5 years from issuance.</td></tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In February 2023, as part of the Company’s initial public offering, the Company issued <span id="xdx_90A_ecustom--ClassOfWarrantOrRightIssued_iI_pid_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--TradeableWarrantsMember_zhret2RYf0Sb" title="Additional shares issued">153,409 tradeable warrants to our underwriters pursuant to the overallotment options with an exercise price of $<span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--TradeableWarrantsMember_zsi8DZhKkDi1" title="Issue price per share">7.80 and an expiration date<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--TradeableWarrantsMember_zcIlMur1wugj" title="Expiration term"> 5 years from issuance. Also in February 2023, as part of the Company’s initial public offering the Company issued <span id="xdx_90E_ecustom--ClassOfWarrantOrRightIssued_iI_pid_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradeableWarrantsMember_zvPhZ1N09SZ2" title="Warrants issued">153,409 non-tradeable warrants to our underwriters pursuant to the overallotment options with an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradeableWarrantsMember_z9L8gFZx7Oh8" title="Issue price per share">8.125 and an expiration date <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20230228__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember__us-gaap--StatementEquityComponentsAxis__custom--NonTradeableWarrantsMember_zY0U7G0dhIm" title="Expiration term">5 years from issuance.</td></tr></table> The following table provides details over the Company’s outstanding warrants including those issued as consideration for services and those issued in conjunction with transactions as of December 31, 2023: Schedule of Outstanding Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: center">$0.0007</td><td style="width: 2%"> </td> <td style="width: 32%; text-align: center">2030</td><td style="width: 2%"> </td> <td style="width: 32%; text-align: right">274,286</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zyCJBzbIQHR4" title="Exercise Price">$2.10 - <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zszIGBJeo3t2" title="Exercise Price">$2.66 </td><td> </td> <td style="text-align: center"><span id="xdx_907_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zGwzG3qNVeoa" title="Expiration Period">2026 - <span id="xdx_904_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zJI5yYSRj9Sb" title="Expiration Period">2032</td><td> </td> <td style="text-align: right">460,445</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zpl7zhQ6Bn7g" title="Exercise Price">$3.36 - <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zimJQXLfWVr1" title="Exercise Price">$4.27 </td><td> </td> <td style="text-align: center"><span id="xdx_90A_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zpwx7kLunYig" title="Expiration Period">2028 - <span id="xdx_904_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_z3MaT19H2DM3" title="Expiration Period">2029</td><td> </td> <td style="text-align: right">115,277</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zwxSJoBP2tXj" title="Exercise Price">$6.51 - <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_z35VmbEIaLJd" title="Exercise Price">$7.80 </td><td> </td> <td style="text-align: center"><span id="xdx_904_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zENNAn9nI0ei" title="Expiration Period">2026 - <span id="xdx_903_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zQ6Qb1m4yze" title="Expiration Period">2032</td><td> </td> <td style="text-align: right">1,484,929</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: center">$8.125</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"><span id="xdx_907_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_zzb3KA5kRoek" title="Expiration Period">2027 - <span id="xdx_90F_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MaximumMember_zUvuwI0E0kmf" title="Expiration Period">2028</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">1,461,227</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">3,796,164</td></tr> </table> During the years ended December 31, 2023 and 2022, the Company recognized $39,265 and $338,142, respectively of compensation expense related to certain warrants. Warrants Issued as Consideration for Services The following table summarizes the activity for warrants issued as consideration for services for the years ended December 31, 2023 and 2022: Schedule of Warrant Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted-Average Remaining Contractual Term (Years)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231_zCCnoqbY6MR9" style="width: 11%; text-align: right" title="Number of Warrants, Outstanding at Beginning">885,373</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zmsNDAEf5Daf" style="width: 11%; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning"> 2.59</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> <span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zlEeBAAAEcL" title="Weighted average remaining life in years, outstanding">7.4</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iS_c20220101__20221231_zolrbFnFREAf" style="width: 11%; text-align: right" title="Aggregate intrinsic value, beginning balance">2,147</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231_zDwwmak8WYji" style="text-align: right" title="Warrants Granted">56,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_fWzRd_zkGGsEkE5XK8" style="text-align: right" title="Weighted average exercise price, granted">3.87</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231_zRcQKQl06DIi" style="text-align: right" title="Number of warrants, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisedPrice_c20220101__20221231_fWzVd_zQzC79Uae6h9" style="text-align: right" title="Weighted average exercise price, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231_zuWL2ImYCli8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, forfeited">(263,826</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_z51dzPPnz0Th" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, forfeited">5.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231_zT94wz15Msg1" style="text-align: right" title="Number of Warrants, Outstanding at Beginning">678,176</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_z2yQFEmT74zj" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">1.57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zjZMH4oAUqEd" title="Weighted average remaining life in years, outstanding">7.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iS_c20230101__20231231_zEJn3HKQhbQf" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning">2,131,123</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231_zARbrCqJ7Lr8" style="text-align: right" title="Number of Warrants, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231_fWzRd_z9JZGYpbTeGj" style="text-align: right" title="Weighted-Average Exercise Price, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231_zuH2foEVaslg" style="text-align: right" title="Number of Warrants, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisedPrice_c20230101__20231231_fWzVd_zu2cgcu5rdKb" style="text-align: right" title="Weighted-Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20231231_zdNeuD6B0zz1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Forfeited / Canceled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zjRlexLHTumf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Forfeited / canceled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231_zG0LHT6CN85i" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding at Ending">678,176</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_zPfCV2q42Vbg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Ending">1.57</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zV41ZZG9k26e" title="Weighted-Average Remaining Contractual Term (Years), Outstanding">6.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iE_c20230101__20231231_ziIfBmlj8bxk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Ending">1,209,136</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingNumber_iE_c20230101__20231231_zJyckcBo7Dof" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Vested at Ending">671,789</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkdohliFWCl4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Vested at Ending">1.56</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zvDpfzFOG3C1" title="Weighted-Average Remaining Contractual Term (Years), Vested">6.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuOi9G2yJxcf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested at Ending">1,205,305</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_899_ecustom--ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock_zTH8Pbu94QOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of options granted in the years ended 2022 were estimated using the Black-Scholes option pricing model based on the assumptions in the table below: Schedule of Warrants Valuation Assumptions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Expected dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: center"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztbfK5jgheLc" title="Expected dividend yield">0%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4MIweQXzaR9" title="Expected volatility">89%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z82Hwb1Yfbl" title="Risk free interest rate, minimum">1.86% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHzKHcQlkPNb" title="Risk free interest rate, maximum">1.97% </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEquf8amxLdg" title="Expeced life (in years)">10</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Volatility - The trading volatility was determined by calculating the volatility of the Company’s peer group.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Expected life of options – The expected life of options granted to employees was determined using the simplified method.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Risk-free interest rate – This is the U.S. Treasury rate, having a term comparable to the expected life of the stock option.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Dividend yield – The Company does not expect to pay a dividend in the foreseeable future.</td></tr></table> No warrants were issued in the year ended December 31, 2023. As of December 31, 2023, the total unrecognized compensation expense related to unvested warrants was approximately $<span id="xdx_902_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20231231__us-gaap--StatementEquityComponentsAxis__custom--UnvestedWarrantsMember_z0ff14KNHGp4" title="Unrecognized compensation expense">3,000, which the Company expects to recognize over a weighted-average period of approximately <span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__custom--UnvestedWarrantsMember_zYxhKnvofoFh" title="Weighted average period term">0.2 years. The total grant-date fair value of warrants vested during the year ended December 31, 2023 was approximately $<span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjpri23LtqCf" title="Fair value of warrants">39,300.

10000000

0.00001

5500000

734492

73449

0.0499

315000

100000000

0.00001

734429

205984

226138

112225

39879

1297318

6.50

8400000

7.80

8.125

331166

1-for-7 reverse split

7692

50000

436533

1494658

3521880

927373

527717

69217

P10Y

900000

0.15

441500

The following tables summarizes the stock option activity for the years ended December 31, 2023 and 2022: Schedule of Stock Options Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted-Average Remaining Contractual Term (Years)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220101__20221231_zsuHvAmpdELg" style="width: 11%; text-align: right" title="Number of Shares, Outstanding at Beginning">468,571</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zs5PmbZrVzR5" style="width: 11%; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">3.32</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zgZt5YxQ5F0e" title="Weighted-Average Remaining Contractual Term (Years), Outstanding">7.4</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231_zJXpHQCfVG3c" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220101__20221231_zBntGRxfUvrl" style="text-align: right" title="Number of Shares, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_zCnMorcpvCFk" style="text-align: right" title="Weighted-Average Exercise Price, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220101__20221231_zeCj1zmvRCri" style="text-align: right" title="Number of Shares, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220101__20221231_z3NIiK5JkPM2" style="text-align: right" title="Weighted-Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220101__20221231_zXIBJxc5eu7j" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeited / canceled">(399,354</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220101__20221231_zGnhALYR3tAe" style="padding-bottom: 1pt; text-align: right" title="Weighted-Average Exercise Price, Forfeited / canceled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230101__20231231_zSfKekbHwti1" style="text-align: right" title="Number of Shares, Outstanding at Beginning">69,217</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_zIxeA20Lv9Xd" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">3.06</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dxL_c20220101__20221231_zlRaFTM3UDYi" style="text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Outstanding::XDX::P7Y0M29D">7.1</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValues_iS_c20230101__20231231_z7wXrWVk0g5c" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230101__20231231_zcsYg3u3KHhf" style="text-align: right" title="Number of Shares, Granted">458,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zGRV3rP07XB6" style="text-align: right" title="Weighted-Average Exercise Price, Granted">4.34</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230101__20231231_zq43BleDPXwj" style="text-align: right" title="Number of Shares, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20230101__20231231_zudJwxIwOxr9" style="text-align: right" title="Weighted-Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230101__20231231_z1suHHybeDh4" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Forfeited / canceled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230101__20231231_zyOtM4zQi4pa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Forfeited / canceled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230101__20231231_zKq0rizFxeja" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Outstanding at Ending">527,717</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_zyxeINC0iPTj" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Ending">4.17</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230101__20231231_ztlTJXPxAQU9" title="Weighted-Average Remaining Contractual Term (Years), Outstanding">9.0</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20231231_zMmsS8HeZ1U8" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Ending">112,141</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20231231_ztfBP9XesUeg" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Vested at Ending">255,826</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_c20231231_z15m19kiaonl" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Vested at Ending">4.01</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zaZlnUJgUfkk" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Remaining Contractual Term (Years), Vested at Ending">8.5</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iI_c20231231_z5Vqu4syE1E6" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested at Ending">62,193</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

468571

3.32

P7Y4M24D

399354

69217

3.06

458500

4.34

527717

4.17

P9Y

112141

255826

4.01

P8Y6M

62193

The fair value of options granted in the year ended December 31, 2023 was estimated using the Black-Scholes option pricing model based on the assumptions in the table below: Schedule of Black Scholes Option Pricing Model <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Expected dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: center">0%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230101__20231231_zSLFaZjtj5g7" title="Expected volatility, minimum">87% - <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230101__20231231_z1Z629kaWfL1" title="Expected volatility, maximum">92%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230101__20231231_ze04FeNnL9Lb" title="Risk-free interest rate, minimum">3.4% - <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230101__20231231_zd4kFfYos6P1" title="Risk-free interest rate, maximum">4.4%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MinimumMember_z3p1QdSVk2N7" title="Expected life (in years)">5.0 - <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__srt--RangeAxis__srt--MaximumMember_zxmyBnyRL8Vk" title="Expected life (in years)">6.0 </td><td style="text-align: left"> </td></tr> </table>

0.87

0.92

0.034

0.044

P5Y

P6Y

3.15

1445200

585500

592268

2010

861000

P1Y10M24D

3195906

415247

P10Y

vest over varying periods up to 24 months from the grant date

27867

39265

350908 337269

51941

11097 42057 1883

431659

200000

12462

P5Y

200000

92859

12980

P5Y

50735

11097 99000

115185

2.50

1.00

15412

195000

225000

2.50

64978

92859

276452

4.27

P5Y

18000

8.125

P4Y

1297318

7.80

P5Y

1297318

8.125

P5Y

153409

7.80

P5Y

153409

8.125

P5Y

The following table provides details over the Company’s outstanding warrants including those issued as consideration for services and those issued in conjunction with transactions as of December 31, 2023: Schedule of Outstanding Warrants <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Exercise Price</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Expiration</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 32%; text-align: center">$0.0007</td><td style="width: 2%"> </td> <td style="width: 32%; text-align: center">2030</td><td style="width: 2%"> </td> <td style="width: 32%; text-align: right">274,286</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zyCJBzbIQHR4" title="Exercise Price">$2.10 - <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zszIGBJeo3t2" title="Exercise Price">$2.66 </td><td> </td> <td style="text-align: center"><span id="xdx_907_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MinimumMember_zGwzG3qNVeoa" title="Expiration Period">2026 - <span id="xdx_904_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceOneMember__srt--RangeAxis__srt--MaximumMember_zJI5yYSRj9Sb" title="Expiration Period">2032</td><td> </td> <td style="text-align: right">460,445</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zpl7zhQ6Bn7g" title="Exercise Price">$3.36 - <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_zimJQXLfWVr1" title="Exercise Price">$4.27 </td><td> </td> <td style="text-align: center"><span id="xdx_90A_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MinimumMember_zpwx7kLunYig" title="Expiration Period">2028 - <span id="xdx_904_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceTwoMember__srt--RangeAxis__srt--MaximumMember_z3MaT19H2DM3" title="Expiration Period">2029</td><td> </td> <td style="text-align: right">115,277</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zwxSJoBP2tXj" title="Exercise Price">$6.51 - <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_z35VmbEIaLJd" title="Exercise Price">$7.80 </td><td> </td> <td style="text-align: center"><span id="xdx_904_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MinimumMember_zENNAn9nI0ei" title="Expiration Period">2026 - <span id="xdx_903_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceThreeMember__srt--RangeAxis__srt--MaximumMember_zQ6Qb1m4yze" title="Expiration Period">2032</td><td> </td> <td style="text-align: right">1,484,929</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt; text-align: center">$8.125</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: center"><span id="xdx_907_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MinimumMember_zzb3KA5kRoek" title="Expiration Period">2027 - <span id="xdx_90F_ecustom--WarrantExpirationPeriod_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ExercisePriceFourMember__srt--RangeAxis__srt--MaximumMember_zUvuwI0E0kmf" title="Expiration Period">2028</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: right">1,461,227</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: center"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: right">3,796,164</td></tr> </table>

0.0007

2030

274286

2.10

2.66

2026 2032

460445

3.36

4.27

2028 2029

115277

6.51

7.80

2026 2032

1484929

8.125

2027 2028

1461227

3796164

39265

338142

The following table summarizes the activity for warrants issued as consideration for services for the years ended December 31, 2023 and 2022: Schedule of Warrant Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center; padding-bottom: 1pt"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold">Weighted-Average Remaining Contractual Term (Years)</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding at December 31, 2021</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20220101__20221231_zCCnoqbY6MR9" style="width: 11%; text-align: right" title="Number of Warrants, Outstanding at Beginning">885,373</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20220101__20221231_zmsNDAEf5Daf" style="width: 11%; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning"> 2.59</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"> <span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_zlEeBAAAEcL" title="Weighted average remaining life in years, outstanding">7.4</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iS_c20220101__20221231_zolrbFnFREAf" style="width: 11%; text-align: right" title="Aggregate intrinsic value, beginning balance">2,147</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20220101__20221231_zDwwmak8WYji" style="text-align: right" title="Warrants Granted">56,629</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20220101__20221231_fWzRd_zkGGsEkE5XK8" style="text-align: right" title="Weighted average exercise price, granted">3.87</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220101__20221231_zRcQKQl06DIi" style="text-align: right" title="Number of warrants, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisedPrice_c20220101__20221231_fWzVd_zQzC79Uae6h9" style="text-align: right" title="Weighted average exercise price, exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20220101__20221231_zuWL2ImYCli8" style="border-bottom: Black 1pt solid; text-align: right" title="Number of warrants, forfeited">(263,826</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left">$</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20221231_z51dzPPnz0Th" style="padding-bottom: 1pt; text-align: right" title="Weighted average exercise price, forfeited">5.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Outstanding at December 31, 2022</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20230101__20231231_zT94wz15Msg1" style="text-align: right" title="Number of Warrants, Outstanding at Beginning">678,176</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20230101__20231231_z2yQFEmT74zj" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding at Beginning">1.57</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zjZMH4oAUqEd" title="Weighted average remaining life in years, outstanding">7.6</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iS_c20230101__20231231_zEJn3HKQhbQf" style="text-align: right" title="Aggregate Intrinsic Value, Outstanding at Beginning">2,131,123</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230101__20231231_zARbrCqJ7Lr8" style="text-align: right" title="Number of Warrants, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20230101__20231231_fWzRd_z9JZGYpbTeGj" style="text-align: right" title="Weighted-Average Exercise Price, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20230101__20231231_zuH2foEVaslg" style="text-align: right" title="Number of Warrants, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisedPrice_c20230101__20231231_fWzVd_zu2cgcu5rdKb" style="text-align: right" title="Weighted-Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited / canceled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230101__20231231_zdNeuD6B0zz1" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Forfeited / Canceled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20230101__20231231_zjRlexLHTumf" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Forfeited / canceled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20230101__20231231_zG0LHT6CN85i" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Outstanding at Ending">678,176</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231_zPfCV2q42Vbg" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Outstanding at Ending">1.57</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_906_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zV41ZZG9k26e" title="Weighted-Average Remaining Contractual Term (Years), Outstanding">6.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iE_c20230101__20231231_ziIfBmlj8bxk" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Outstanding at Ending">1,209,136</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Vested at December 31, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantVestedAndExpectedToVestOutstandingNumber_iE_c20230101__20231231_zJyckcBo7Dof" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Warrants, Vested at Ending">671,789</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkdohliFWCl4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted-Average Exercise Price, Vested at Ending">1.56</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zvDpfzFOG3C1" title="Weighted-Average Remaining Contractual Term (Years), Vested">6.6</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuOi9G2yJxcf" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value, Vested at Ending">1,205,305</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

885373

2.59 P7Y4M24D 2147

56629

3.87

263826

5.50

678176

1.57 P7Y7M6D 2131123

678176

1.57 P6Y7M6D 1209136 671789 1.56 P6Y7M6D 1205305 <p id="xdx_899_ecustom--ScheduleOfShareBasedPaymentAwardNonOptionEquityInstrumentsValuationAssumptionsTableTextBlock_zTH8Pbu94QOi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of options granted in the years ended 2022 were estimated using the Black-Scholes option pricing model based on the assumptions in the table below: Schedule of Warrants Valuation Assumptions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">Expected dividend yield</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: center"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztbfK5jgheLc" title="Expected dividend yield">0%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4MIweQXzaR9" title="Expected volatility">89%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z82Hwb1Yfbl" title="Risk free interest rate, minimum">1.86% - <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zHzKHcQlkPNb" title="Risk free interest rate, maximum">1.97% </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: center"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEquf8amxLdg" title="Expeced life (in years)">10</td><td style="text-align: left"> </td></tr> </table>

0.89

0.0186

0.0197

P10Y

3000

P0Y2M12D

39300

9. Income Taxes Deferred income taxes reflect the net tax effects of loss and credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets for federal and state income taxes are as follows: Schedule of Deferred Tax Assets And Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20231231_zyzujMyRr5E6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20221231_z9J8GZlw0hQd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzmBF_zrv4Pco9uKlc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: left">Net operating losses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,432,634</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">924,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzmBF_zVM18ie556ui" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Capitalized research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">283,353</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzmBF_zgqxabDHGPEb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,213</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGzmBF_zXv3EpaUZTCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">173,273</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzmBF_zqypCIUEOzSj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,438</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzmBF_maDTANz11O_zck2g1frgpqc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,073,911</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">924,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz11O_zT6Bu4oJkts8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,073,459</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(924,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz11O_maDTALNzM2Y_z4hVQ8RhCON6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net deferred tax asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">452</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di_maDITLz91n_z9UUsuwauYE" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Property and equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(452</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLz91n_msDTALNzM2Y_z8OJHMoNRrLg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(452</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzM2Y_zQTGwIWks8qf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset / (liability)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Realization of our deferred tax assets is dependent upon future earnings, if any, the timing, and amount of which are uncertain. Because of our lack of U.S. earnings history, the net U.S. deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $1,151,827 and $585,000 during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $6.1 million and a total state net operation loss carryforward of approximately $2 million. The net operating loss carryforwards do not expire and may be used to offset future taxable income. Utilization of some of the federal and state net operating loss carryforwards are subject to annual limitations due to the “change in ownership” provisions of the Internal Revenue Code of 1986 and similar state provisions. The annual limitations may result in the expiration of net operating losses and credits before utilization. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management, based upon the earnings history of the Company; it is more likely than not that the benefits will not be realized. All or portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits. We have incurred net operating losses since inception and we do not have any significant unrecognized tax benefits. Our policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations. If we are eventually able to recognize our uncertain positions, our effective tax rate would be reduced. We currently have a full valuation allowance against out net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future. Any adjustments to our uncertain tax positions would result in an adjustment of our net operating loss or tax credit carry forwards rather than resulting in a cash outlay. We file income tax returns in the U.S. and certain state jurisdictions. We are not currently under examination in these jurisdictions for any tax year. The Company’s tax years beginning with 2020 are open tax years. Because of net operating losses and research credit carryovers, substantially all of our tax years remain open to examination. The Company did not have unrecognized tax benefits as of December 31, 2023 and 2022, and does not anticipate this to change significantly over the next 12 months. The Company will recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. Reconciliations between the statutory federal income tax rate and the effective income tax rate of income tax expense is as follows: Effective Income Tax Rate of Income Tax Expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">U.S. Federal statutory tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1.1</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3.3</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16.6</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>

Schedule of Deferred Tax Assets And Liabilities <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20231231_zyzujMyRr5E6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20221231_z9J8GZlw0hQd" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2022</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Deferred tax assets:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTAGzmBF_zrv4Pco9uKlc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 64%; text-align: left">Net operating losses</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,432,634</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">924,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_maDTAGzmBF_zVM18ie556ui" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Capitalized research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">283,353</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTAGzmBF_zgqxabDHGPEb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,213</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_maDTAGzmBF_zXv3EpaUZTCb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Intangibles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">173,273</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_maDTAGzmBF_zqypCIUEOzSj" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">9,438</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsGross_iTI_mtDTAGzmBF_maDTANz11O_zck2g1frgpqc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total deferred tax assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,073,911</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">924,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANz11O_zT6Bu4oJkts8" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,073,459</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(924,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANz11O_maDTALNzM2Y_z4hVQ8RhCON6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net deferred tax asset</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">452</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Deferred tax liabilities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_di_maDITLz91n_z9UUsuwauYE" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt">Property and equipment</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(452</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredIncomeTaxLiabilities_iNTI_di_mtDITLz91n_msDTALNzM2Y_z8OJHMoNRrLg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total deferred tax liabilities</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(452</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_mtDTALNzM2Y_zQTGwIWks8qf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset / (liability)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1432634

924000

283353

175213

173273

9438

2073911

924000

2073459

924000

452

1151827

585000

6100000

2000000

Effective Income Tax Rate of Income Tax Expense <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">U.S. Federal statutory tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1.1</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3.3</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(16.6</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr> </table>

0.210

-0.011

-0.033

-0.166

10. Material Agreements JHU-APL Technology License On February 7, 2018, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the technology. The license covers three (3) issued patents, one (1) new provisional patent application, non-patent rights to proprietary libraries of algorithms and other trade secrets, the license also includes modifications and improvements. In October of 2021, the Company executed an amendment to the original license which represents improvements and new advanced analytics capabilities. In consideration of the rights granted to the Company under the License Agreement JHU received a warrant equal to five percent (5%) of the then fully diluted equity base of the Company, which shall be diluted following the closing of the IPO. Under the terms of the License Agreement, JHU will be entitled to eight percent (8%) royalty on net sales for the services provided by the Company in which the JHU licensed technology was utilized, as well as fifty percent (50%) of all sublicense revenues received by the Company. In addition, the Company is required to pay JHU an annual maintenance fee of $1,500. Minimum annual royalty payments are $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20211001__20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyTwoMember_zV3ImqhLGhO2" title="Royalty payments for 2022">20,000 for 2022, $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20211001__20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyThreeMember_zjHiD60azjEa" title="Royalty payments for 2023">80,000 for 2023, and $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20211001__20211031__us-gaap--TypeOfArrangementAxis__custom--JHUAPLTechnologyLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyFourMember_z6Nzw0QyRD4" title="Royalty payments for 2024">300,000 for 2024 and beyond, if cumulative annual royalty payments do not reach these levels, the amount due to JHU to reach the annual minimum is due by January 31st of the following year. Failure to make annual royalty payments is considered a material breach under the agreement and upon notice from JHU of a material breach, the Company shall have 60 days to cure the material breach. On July 8, 2022, the company entered into an exclusive, world-wide, royalty-bearing license from JHU-APL for the additional technology developed to enhance the bfLEAP™ platform. The new license provides additional intellectual property rights including patents, copyrights, and knowhow to be utilized under the Company’s bfLEAP™ analytical AI/ML platform. This license supersedes the previous license. In consideration of the new license, the Company issued 39,879 shares of common stock. Under the terms of the new License Agreement, JHU will be entitled to eight percent (<span id="xdx_90E_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__srt--TitleOfIndividualAxis__custom--OtherPartiesMember_z2LbKESxYJt1" title="Royalty percent">8%) of net sales for the services provided by the Company to other parties and three percent (<span id="xdx_90E_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis__custom--InternallyDevelopmentDrugProjectsMember_z76rdlEWWNjh" title="Royalty percent">3%) for internally development drug projects in which the JHU license was utilized. The new license also contains tiered sub licensing fees that start at 50% and reduce to <span id="xdx_905_ecustom--IncreaseDecreaseInSublicensePercentageBasedOnRevenues_iI_pid_dp_uPure_c20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__srt--RangeAxis__srt--MinimumMember_zFHRIC7N3ymi" title="Sublicense fee based on revenue">25% based on revenues. In addition, under the new license agreement, the minimum annual royalty payments are $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20220708__20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyTwoMember_zu6OFg9n3mRk" title="Royalty payments">30,000 for 2022, $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20220708__20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyThreeMember_zQLjzq56zzAk" title="Royalty payments">60,000 for 2023, and $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20220708__20220708__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyFourMember_zEIj2lgAEPtg" title="Royalty payments">300,000 for 2024 and beyond. On May 31, 2023, the Company and JHU-APL entered into Amendment number 1 of the July 8, 2022 License Agreement whereby the Company gained access to certain improvements including additional patents and knowhow in exchange for a series of payments totaling $275,000. The first of these payments for $<span id="xdx_904_eus-gaap--RoyaltyExpense_c20230530__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyThreeMember_zhcDFvM1yKbe" title="Royalty payments">75,000 was due in July 2023 followed by payments of <span id="xdx_901_eus-gaap--RoyaltyExpense_c20230530__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyFiveMember_zrkV8HmFnWV" title="Royalty payments">$75,000, $<span id="xdx_90B_eus-gaap--RoyaltyExpense_c20230530__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentySixMember_zLHgvp8TWepe" title="Royalty payments">75,000, and $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20230530__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentySevenMember_zwoRJNA5P9Ih" title="Royalty payments">50,000 in years 2025, 2026 and 2027, respectively. The amendment also reduced the 2023 minimum annual royalty payment to $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20230530__20230531__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyTwoMember_zFyePDugeWSh" title="Royalty payments">60,000, all other financial terms remain the same. As of December 31, 2023, we have accrued $<span id="xdx_906_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--NewLicenseAgreementMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyThreeMember_zs6bXUXHKin3" title="Accrued royalty payments">60,000 of the 2023 minimum annual royalty payments. George Washington University - Beta2-spectrin siRNA License On January 14, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from George Washington University (GWU) for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma (HCC). The license covers methods claimed in three US and worldwide patent applications, and also includes use of this approach for treatment of obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. In consideration of the rights granted to the Company under the License Agreement the Company paid GWU a $20,000 License Initiation Fee. Under the terms of the License Agreement, GWU will be entitled to a three percent (<span id="xdx_90E_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220114__us-gaap--TypeOfArrangementAxis__custom--GeorgeWashingtonUniversityBeta2SpectrinSiRNALicenseMember_zA8CFXnO8Vid" title="Royalty percent">3%) royalty on net sales subject to quarterly minimums once the first sale has occurred subsequent to regulatory approval, as well sublicense or assignment fees in the event the Company sublicenses or assigns their rights to use the technology. The Company will also reimburse GWU for previously incurred and ongoing patent costs. The Sublicense and Assignment fee amounts decline as the Company advances the clinical development of the licensed technology. The license agreement also contains milestone payments for clinical development through the approval of an NDA and commercialization. As of December 31, 2023 and 2022, there has been no accrual for royalties since we have not begun to generate applicable revenue. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely. Johns Hopkins University – Mebendazole License On February 22, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from Johns Hopkins University (JHU) for the use of an improved formulation of Mebendazole for the treatment of any human cancer or neoplastic disease. This formulation shows potent activity in animal models of different types of cancer and has been evaluated in a Phase I clinical trial in patients with high-grade glioma (NCT01729260). The trial, an open-label dose-escalation study, assessed the safety and efficacy of the improved formulation with adjuvant temozolomide in 24 patients with newly diagnosed gliomas. Investigators observed no dose-limiting toxicity in patients receiving all but the highest tested dose (200mg/kg/day). Four of the 15 patients receiving the maximum tested dose of 200mg/kg/day experienced dose-limiting toxicity, all of which were reversed by decreasing or eliminating the dose given. There were no serious adverse events attributed to Mebendazole at any dose during the trial. 41.7% of patients who received Mebendazole were alive at two years after enrollment, and 25% were alive at four years (Gallia et al., 2021). The license covers six (6) issued patents and one (1) pending application. In consideration of the rights granted to the Company under the License Agreement, JHU will receive a staggered Upfront License Fee of $250,000. The initial payment for $50,000 was paid and the remaining balance of $200,000 was paid after the Company completed its IPO. The Company will also reimburse JHU for previously incurred and ongoing patent costs. Under the terms of the License Agreement, JHU will be entitled to three and one-half percent (<span id="xdx_907_ecustom--PercentageOfRoyaltyOnNetSales_iI_pid_dp_uPure_c20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zkza4lIB93zd" title="Royalty percent">3.5%) royalty on net sales by the Company. In addition, the Company is required to pay JHU minimum annual royalty payments of <span id="xdx_904_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyThreeMember_zIURbqc4cFK3" title="Royalty payments">$5,000 for 2023, $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyFourMember_zwnt3325TtSf" title="Royalty payments">10,000 for 2024, $<span id="xdx_906_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyFiveMember_zttNP5TNnYbf" title="Royalty payments">20,000 for 2025, $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentySixMember_zr5jgpekJW7f" title="Royalty payments">30,000 for 2026 and $<span id="xdx_903_eus-gaap--RoyaltyExpense_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentySevenMember_zgQg2lPzXNzc" title="Royalty payments">50,000 for 2027 and each year after until the first commercial sale after which the annual minimum royalty shall be $<span id="xdx_901_eus-gaap--PaymentsForRoyalties_c20220222__20220222__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zB2x2VLFF6Lg" title="Annual minimum royalty payment">250,000. The license agreement also contains milestone payments for clinical development steps through the approval of an NDA and commercialization. As of December 31, 2023 and 2022, the balance of accrued expense related to this license agreement was $<span id="xdx_900_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_c20231231__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zNN44EW6YLea" title="Accrued royalty expenses">10,000 and $<span id="xdx_907_eus-gaap--AccruedRoyaltiesCurrentAndNoncurrent_iI_c20221231__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityMebendazoleLicenseMember_zqBLzC06guh9" title="Accrued royalty expenses">242,671, respectively. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely. Johns Hopkins University – Prodrug License On October 13, 2022, the Company entered into an exclusive, world-wide, royalty-bearing license from JHU and the Institute of Organic Chemistry and Biochemistry (IOCB) of the Czech Academy of Sciences for rights to commercialize N-substituted prodrugs of Mebendazole that demonstrate improved solubility and bioavailability. The license covers prodrug compositions and use for treating disease as claimed in multiple US and worldwide patent applications. In consideration for the rights granted to the Company under the License Agreement JHU and IOCB will receive a staggered upfront license fee of $100,000. The Company will also reimburse JHU and IOCB for previously incurred patent costs. Under the terms of the License Agreement, JHU and IOCB will be entitled to four percent (4.0%) royalty on net sales by the Company. In addition, the Company is required to pay JHU and IOCB minimum annual royalty payments of $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentySevenMember_zobONsSDDf15" title="Royalty payments">5,000 for 2027, $<span id="xdx_90E_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyEightMember_zQ6olevh1Sd2" title="Royalty payments">10,000 for 2028, $<span id="xdx_902_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyTwentyNineMember_z3MgC2b4Oh0j" title="Royalty payments">20,000 for 2029, $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyThirtyMember_zHMTNbvtj0f8" title="Royalty payments">30,000 for 2030 and $<span id="xdx_90C_eus-gaap--RoyaltyExpense_c20221011__20221013__us-gaap--TypeOfArrangementAxis__custom--JohnsHopkinsUniversityProdrugLicenseMember__us-gaap--AwardDateAxis__custom--YearTwentyThirtyOneMember_zDfXu9Vr7K5h" title="Royalty payments">50,000 for 2031 and each year after until the first commercial sale after which the annual minimum royalty shall be $150,000. The license agreement also contains milestone payments for patent grants, clinical development steps through the approval of an NDA and commercialization. As of December 31, 2023 and 2022, the balance of accrued expense related to this license agreement was $0 and $133,238, respectively. The Company assessed whether the license should be capitalized and determined that the licensed program is in the early stage and therefore may not be recoverable; the Company expensed the license fee and will expense development costs until commercial viability is likely. 0.05 0.08 0.50

1500

20000

80000

300000

39879

0.08 0.03 0.50 0.25

30000

60000

300000

275000

75000

50000

60000

20000 0.03

250000

50000

200000

0.035

5000

10000

20000

30000

50000

250000

10000

242671

100000 0.040

5000

10000

20000

30000

50000

150000

133238

11. Commitments and Contingencies While not assured, management does not believe, based upon information available at this time, that a loss contingency will have a material adverse effect on the Company’s financial position, results of operations or cash flows. Additionally, the Company does not have any material commitments.

12. Subsequent Events On February 5, 2024 the Company received net proceeds of approximately $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zvKPbyUOcXgb" title="Net proceeds from offering">4.9 million dollars from an underwritten public offering of <span id="xdx_90C_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240229__20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zvgfQXZtsaq8" title="Shares issued in offering">1,507,139 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants to purchase <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zAKDZHon7sQf" title="Warrants to purhcase common stock">1,507,139 shares of common stock at an offering price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zm1XcHA1aP1f" title="Offering price per share">3.782. The <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_pid_dtY_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zOkEO2sTxUq9" title="Warrants term">5 year warrants have an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20240229__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__custom--UnderwrittenPublicOfferingMember_zDuksRzQJXH3" title="Exercise price of warrant">4.16. On February 21, 2024, the underwriters elected to take an overallotment of <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20240221__20240221__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_zx0XL4lY5qX4" title="Number of shares issued">218,382 common shares and the Company received net proceeds of approximately $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20240221__20240221__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--OverAllotmentOptionMember_z4hFKjJsa8Gk" title="Net proceeds from share issuance">750,000.

4900000

1507139

3.782

P5Y

4.16

218382

750000